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INTRODUCTION 
The Inflammatory Myopathies encompass a group of heterogenous 
muscle disorders which share the clinical features of slowly progressive 
weakness of skeletal muscle, decreased muscle endurance and muscle fatigue. 
Another common feature is presence of inflammatory infiltrates, mainly 
composed of T cells and macrophages, in muscles tissue. Autoantibodies are  
also frequent in patients with inflammatory myopathies. The presence of 
infiltrating lymphyocytes in the target organ, the muscles, and autoimmune 
disease but a target autoantigen has not been determined. 
Although muscle symptoms predominate in myositis patients, other 
clinical manifestations are common. Besides skin rash, which by definition is 
present in dermatomyositis patients, interstinal lung disease is a frequently 
observed extramuscular manifestations, as are arthritis, Raynaud’s 
phenomenon and gastrointestinal involvement. Moreover, myositis is often 
observed in patients with other connective tissue diseases, particularly in 
those with systemic sclerosis, mixed connective tissue disease (MCTD) and 
Sjogren’s syndrome and occasionally in patients with rheumatoid arthritis 
(RA) or systemic lupus erythematosus (SLE). These observations suggests 
that the idiopathic inflammatory myopathies are systemic inflammatory 
connective tissue disorders and that there could be etiological factors or 
pathogenic mechanisms that are shared with other connective tissue diseases. 
In our study we attempt to find out the incidence, prevalence of 
cardiopulmonary manifestations in inflammatory myositis. 
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AIM AND OBJECTIVES 
To determine the various cardiopulmonary manifestations in 
inflammatory myosit is. 
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REVIEW OF LITERATURE 
ANATOMY AND PHYSIOLOGY OF MUSCLE 
Embryology and molecular regulation of muscle development 
The muscular system develops from the mesodermal germ layer1 and 
consists of skeletal, smooth, and cardiac muscle. Skeletal muscle is derived 
from paraxial mesoderm, which forms somites from the occipital to the sacral 
regions and somitomeres in the head. Smooth muscle differentiates from 
splanchnic mesoderm surrounding the gut and its derivatives and from 
ectoderm (papillary, mammary gland, and sweat gland muscles). Cardiac 
muscle is derived from splanchnic mesoderm surrounding the heart tube. 
 
Schematic diagram of muscle bindle 
Somites and somitomeres form the musculature of the axial skeleton, 
body wall, limbs and head. From the occipital region caudally, somites form 
and differentiate into the sclerotome, dermatome, and two muscle-forming 
region. One of the regions appears at the ventrolateral edge or lip (VLL) of 
the prospective dermomyotome. Cells from the VLL contribute to formation 
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of the myotome and also provide progenitor cells for limb and body wall 
(Hypometric, hypaxial) musculature. The other region lies at the dorsomedial 
edge or lip (DML) of the dermomyotome, and dermatome. Eventually, these 
cells will form muscles of the back. During differentiation, precursor cells,  
the myoblasts, fuse and form long, multinucleated muscle fibers. Myofibrils 
soon appear in the cytoplasm, and by the end of the third month, cross 
striations, typical of skeletal muscle, appear .A similar process occur in the 
seven somitomeres in the head region rostral to the occipital somites. 
However somitomeres remain loosely organized structures and never 
segregate into sclerotome and dermomyotome segments. Tendon for the 
attachment of muscles to bones are derived from sclerotome cells lying 
adjacent to myotomes at the anterior and posterior borders of sometimes. The 
transcription factors scleraxis regulates development of these cells. 
GENETIC FACTORS IN MUSCLE DEVELOPMENT 
Genes regulating muscle development are bone morphogenic protein 4 
(BMP4) and probably fibroblast growth factors (FGFs) from lateral plate 
mesoderm together with WNT proteins from adjacent ectoderm, signal 
ventrolateral edge or lip (VLL) cells of the dermomyotome to express the 
muscle-specific genes Myogenic factor-4 (MYF4) and Myogenesis 
determining factor (MYO-D2). BMP4 secreted by ectoderm cells induces 
production of WNT protein by the dorsal neural tube at the same t ime that 
low concentrations of sonic hedgehog (SHH) proteins, secreted by the 
notochord and floor plate of the neural tube, reach the dorsomedial edge or lip 
(DML) cells of the dermomyotomes. Together these proteins induce 
expression of MYF5 and MYO-D in these cells. Both MYO-D and MYF5 are 
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numbers of a family of transcript ion factors called myogenic regulatory 
factors (MRF) and it is this group of genes that activate pathways for muscle 
development. 
Muscle is generally divided into three types, Skeletal, Cardiac and 
Smooth, though smooth muscle is not a homogenous single category. Skeletal 
muscle makes up the great mass of the somatic musculature. It has well 
developed cross striations, does not normally contract in the absence of 
nervous stimulation, lacks anatomic and functional connections between 
individual muscle fibers, and is generally under voluntary control. Cardiac 
muscle also has cross striations, but it is functionally syncytial and contracts 
rhythmically in the absence of external innervations owing to the presence in 
the myocardium of pacemaker cells that discharge spontaneously. Smooth 
muscle lacks cross-striations, which is found in most hollow viscera. The type 
found in the eye and in some other locations is not spontaneously active and 
resembles skeletal muscle. 
MORPHOLOGY 
Organization 
Skeletal muscles is made up of individual muscle fibers that are the 
“building blocks” of the muscular system2 in the same sense that the neurons  
are the building blocks of the nervous system. Most skeletal muscle begin and 
end in tendons, and the muscle fibers are arranged in parallel between the 
tendinous ends, so that the force of contractions of the units is additive. Each 
muscle fiber is a single cell that is multinucleated, long, cylindric, and 
surrounded by a cell membrane, the sarcolemma. There are no syncytial 
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bridges between cells. The muscle fibers are made up of myofibrils, which are 
divisible into individual filaments. The filaments are made up of the 
contractile proteins. 
The contractile mechanism in skeletal muscle depends on the proteins 
myosin-II (molecular weight 40,000kda) actin (molecularweight 43,000kda) 
tropomyosin (Molecularweight 70,000kda) and troponin. Troponin is made up 
of three subunits; troponin-I, troponin T and troponin C. The three subunits 
have molecularweights ranging from 18,000kda to 35,000kda. Other 
important proteins in muscle were involved in maintaining the contractile 
proteins in appropriate relation to one another and connected to the external 
matrix. 
STRIATIONS 
Difference in the refractive indexes of the various parts of the muscle 
fibers2 are responsible for the characteristic cross-striations seen in skeletal 
muscle. The parts of the cross striations are identified by letters. The light   
I band is divided by the dart Z line, and the dark A band has the lighter H 
band in its center. A transverse M line is seen in the middle of the H band, 
and this line plus the narrow light areas on either side of it are sometimes 
called the pseudo-H zone. The area between two adjacent Z lines is called a  
sarcomere. The orderly arrangement of actin, myosin, and related proteins 
that produce this pattern. The thick filaments, which are about twice the 
diameter of the thin filaments are made up of actin, tropomyosin forms the 
less dense I bands. The lighter H bands in the centre of the A bands are the 
regions where, when the muscle is relaxed, the thin filaments do not overlap 
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the thick filaments. The Z lines transect the fibrils and connect to the thin 
filaments. If a transverse section through the A band is examined under the 
electron microscope, each thick filament is seen to be surrounded by six thin 
filaments in a regular hexagonal pattern. 
The form of myosin found in muscle is myosin-II, with two globular 
heads and a long tail. The heads of the myosin molecules form cross- links to 
actin. Myosin contains heavy and light chains and its heads are made up of 
the light chains and the amino terminal portions of the heavy chains. These 
heads contains an actin-binding site and a catalytic site that hydrolyzes ATP. 
The myosin molecules are arranged symmetrically on either side of the centre 
of the sarcomere, and it is this arrangement that creates the light areas in the 
pseudo H zone. The M line is the site of the reversal of polarity of the myosin 
molecules in each of the thick filaments. At this point, there are slender cross- 
connections that hold the thick filaments in proper array. Each thick segment  
contains several hundred myosin molecules. The thin filaments are polymers 
made up of two chains of actin that form a long double helix. Tropomyosin 
molecules are long filaments located in the groove between the two chains in 
the actin. Each thin filament contains 300-400 actin molecules and 40-60 
tropomyosin molecules. Troponin molecules are small globular nits located at 
intervals along the tropomyosin molecules. Troponin T binds the other 
troponin components to tropomyosin, troponin I inhibits the interaction of 
myosin with actin, and troponin C contains the binding sites for the Ca2+ that 
init iates contractions.  
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Actinin, which has a molecular weight of 1,90,000kda binds actin to 
the Z lines. Tit in, a large protein connects the Z lines to the M lines and 
provides the scaffolding for the sarcomere. It contains two kinds of folded 
domains, and these provide muscle with its elasticity. At first when the 
muscle is stretched there is relatively little resistance as the domains unfold, 
but with further stretch there is a rapid increase in resistance that protects the 
structure of the sarcomere. Desmin binds the Z lines to the plasma membrane. 
SARCOTUBULAR SYSTEM 
The muscle fibrils are surrounded by structures made up of membrane 
that appear in electron photomicrographs as vesicles and tubules. These 
structures from the sarcotubular system2, which is made up of a T system and 
a sarcoplasmic reticulum. The T system of transversetubules, which is 
continuous with the membrane of the muscle fiber, forms a grid perforated by 
the individual muscle fibrils. The space between the two layers of the T 
system is an extension of the extracellular space. The sarcoplasmic reticulum, 
which forms an irregular curtain around each of the fibrils, has enlarged 
terminal cisterns in close contacts with the T system with a cistern of the 
sarcoplasmic reticulum on either side has led to the use of the term triads to 
describe the system. The function of the T system, which is continuous with 
the sarcolemma, is the rapid transmission of the action potential from the cell 
membrane to all the fibrils in the muscle. The sarcoplasmic reticulum is 
concerned with Ca2+ movement and muscle metabolism. 
A large protein called dystrophin (molecular weight 4,27,000kda) 
forms a rod that connects the thin actin filaments to the transmembrane 
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protein   dystroglycan in the sarcolemma. -dystroglycan is connected to 
laminin in the extracellular matrix by -dystroglycan. 
MOLECULAR BASIS OF CONTRACTION 
The process by which the shortening of the contractile elements in 
muscles is brought about is a sliding of the thin filaments over the thick 
filaments. The width of the A bands is constant, whereas the Z lines move 
closer together when the muscle contracts and farther apart when it is 
stretched. 
The sliding during muscle contraction occurs when the myosin heads 
bind firmly to actin, bend at the junction of the head with the neck, and then 
detach. The “Power stroke” depends on the simultaneous hydrolysis of ATP. 
Myosin-II molecules are dimers that have two heads, but only one attachés to 
actin at a time. Many heads cycle at or near the same time, and they cycle 
repeatedly, producing gross muscle contraction. Each stroke shortness the 
sarcomere about 10nm. Each thick filament has about 500 myosin heads, and 
each head cycles about five times per second during a rapid contraction. 
The process by which depolarization of the muscle fiber initiates 
contraction is called excitation contraction coupling. The action potential is 
transmitted to all the fibrils in the fiber via the T system. It  triggers the 
release of Ca2+ which initiates contraction by binding to troponin C. In rest ing 
muscle, troponin I is t ightly bound to actin and tropomyosin covers the sites 
where myosin heads bind to actin. Thus, the troponin- tropomyosin complex 
consistutes a “relaxing protein” that inhibits the interaction between actin and 
myosin. When the Ca2+ released by the action potential binds to troponin C, 
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the binding of troponin I to actin is presumably weakened, and this permits 
the tropomyosin to move laterally. This movement uncovers binding sites for 
the myosin heads. ATP is then split and contraction occurs.Seven myosin- 
binding sites are uncovered for each molecule of troponin that binds a  
calcium ion. 
Short ly after releasing Ca2+, the sarcoplasmic reticulum begins to 
reaccumulate it by ATP mediated active transport of it stored until released 
by the terminal cisterns, where it is stored until released by the next action 
potential. Once the Ca2+ concentration outside the reticulum has been lowered 
sufficiently, chemical interaction between myosin and actin causes and the 
muscle relaxes. Note that ATP provides the energy for both contractions and 
relaxation. If transport of Ca2+ into the reticulum is inhibited, relaxation does 
not occur ever thought there are no more action potentials; the result ing 
sustained contraction is called contracture. 
Depolarization of the T tubule membrane activates the sarcoplasmic 
reticulum via dihydropyridine receptors, named for the drug dihydropyridine, 
which blocks them. They are voltage gated Ca2+ channels in the T tubule 
membrane. In cardiac muscle, influx of Ca2+ via these channels triggers the 
release of Ca2+ stored in the sarcoplasmic reticulum, but in skeletal muscle 
Ca2+ entry from the ECF by this route is not required for Ca2+ release. 
Instead, the dihydropyridine receptor serves as the voltage sensor and trigger 
that unlocks released of Ca2+ from the nearby sarcoplasmic reticulum. The 
Ca2+ Channel in the sarcoplasmic reticulum. The Ca2+ channel in the 
sarcoplamic reticulum that opens to permit the outpouring of Ca2+ is not  
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voltage gated and is called the ryanodine receptors because it is called the 
open position by the plant alkaloid ryanodine. It is closely released to the  
IP3 (Inosine Phosphate) receptor, a ligand-gated Ca2+ channel that, when it binds 
IP3 (Inosine Phosphate) permits Ca2+ to enter the cytoplasm from the 
endoplasmic reticulum. The pump that moves Ca2+ back into the reticulum, 
producing relaxation, is a Ca2+, Mg2+, AT Pase. 
FIBER TYPES2 
Skeletal muscle is a very heterogenous tissue made up of fibers that 
vary in myosin ATPase activity, contractile speed and other properties. The 
fibers fall roughly into two types slow type-I, fast type-IIA and fast type-IIB. 
A fourth fiber type defined by mATPase reactivity, is an intermediate, 
undifferentiated type-IIC fiber. Type-IIC fibers are regarded as transition 
fibers which can develop into type-I or type II fibers. Type I fibers contains 
the slow myosin heavy chain isoform an D-type II fibers contains the fast  
myosin heavy chain isoform. Type-IIC fibers contain at least two different 
myosin isoforms as well as developmental fetal myosin. Fiber types can also 
be separated using biochemical staining for mATPase at different pH values 
depending on the varying pH sensitivity of different mATPase reactivity. 
The different fiber types exhibit various physiological properties. Thus 
type I fibers, slow twitch are characterized by relatively low mATPase 
activity and large and numerous mitochondria, making these fibers fatigue 
resistant and suitable for prolonged aerobic exercise and endurance work. 
Type II fibers, on the other hand, have a high mATPase activity rely mainly 
on glycolytic systems for energy supply and are important for quick powerful 
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actions. The specificity of fiber type in a muscle is determined during 
development in the embryonic muscle and seems to be genetically 
determined. 
Each muscle is composed of a mixture of type I and II fibers, creating 
a checkerboard pattern. The ratio between the fiber types determines the 
physiological properties of the muscle. Here are large inter individual 
variations in fiber type composition, it is advantageous for different purposes. 
For example, marathon runners have a predominance of slow twitch, type-I 
fibers whereas athlete sprinters and ice hockey players have a predominance 
of fast-twitch, type-II fibers. There is a tendency to gender differences, with 
more type-I fibers in women than in men. 
MUSCLE DEVELOPMENT AND REGENERATION2 
During development, muscles are composed of single nucleated 
myoblasts that fuse into mult inucleated myotubes, which differentiate into 
mature muscle fiber. The phenotype of a developing muscle fiber differs from 
mature muscle fibers concerning, the expansion of molecules on the cell 
surface as well as in the cytoplasum or the sarcoplasm. One characteristic 
phenotype of mature, differentiated muscle fibers is the absence of major 
histocompatibility complex (MHC) class I molecules (human leukocyte 
antigen (HLA) A, B, C). MHC class I molecules are expressed on all 
nucleated cells in the body, with a few exceptions such as nerve cells and 
muscle cells. One important function of MHC class I molecules is to present 
endogenous antigens to the immune system via interactions with T cell 
receptors. The role of MHC class I molecules during development of muscle 
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fibers and why in nature muscle fibers lose MHC class I expression during 
differentiation is not known. 
Muscle has a regenerating capacity depending on satellite cells, a kind 
of reserve cell localized under the basal lamina of the muscle fiber. Upon 
appropriate stimuli, these satellite cells can grow and fuse with the fiber or 
develop into new adult muscles cells, a process termed regeneration. 
Regenerting fibers are often found in muscle biopsies from patients with 
inflammatory myopathies.  
Classification of fiber types in skeletal muscles 
 Type-I Type-II 
Other names Slow; 
oxidative; 
red 
Fast; 
glycolytic; 
white 
Myosin isoenzyme ATPase rate Slow Fast 
Ca2+ pumping capacity of sarcoplasmic 
reticulum 
Moderate High 
Diameter Moderate Large 
Glycolyt ic capacity Moderate High 
Oxidative capacity (correlates with content 
of mitochondria, capillary density, 
myoglobin content) 
High  Low 
ANATOMY AND PHYSIOLOGY OF HEART 
EMBRYOLOGY OF HEART1 
The heart is seen to develop first as two ended, helical heart tubes in 
the splanchnopleuric mesoderm (cardiogenic tissue), ventral to the pericardial 
cavity, but dorsal to the yolk sac. The two tubes soon fuse together in a  
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craniocaudal direction to form a single tubular heart, the lining cells form the 
endocardial lining of the heart. 
ANATOMY OF HEART 
Heart is a hallow muscular organ situated in the middle mediastinum 
inside the periocardium. It is conical in shape it has an apex formed by left 
ventricle, a base formed by posterior wall of left atrium the small part of the 
right atrium. Pulmonary veins enter the left atrium. The superior and inferior 
venae-cavae enter the right atrium above and below. It has four chambers two 
atria and two ventricles in the heart. Atria are above and behind the 
ventricles. Anterior surface is bound by a part of atrium and ventricle. 
Inferior surface is found by right ventricle and the left two third of the left 
ventricle. Pericardium is a fibrous sac which invests and protects the heart in 
the roots of great vessels. Heart is supplied by branches in the superficial and 
the deep cardiac plexuses. The blood supply of the heart is mainly by right  
and left coronary arteries. The venous drainage of the heart is mainly through 
coronary sinus and anterior cardiac veins. The lymphatic drainage of the heart 
is superior mediastinal nodes and right tracheobronchial nodes. The 
conducting system of the heart atrial node, AV node, AV bundle and Purkinje 
fibers.  
MORPHOLOGY OF CARDIAC MUSCLE 
The striations in cardiac muscle are similar to those in skeletal muscle, 
and Z lines were present. Large numbers of elongated mitochondria are in 
close contact with the muscle fibrils. The muscle fibers branch and 
interdigitate, but each is a complete unit surrounding by a cell membrane. 
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Where the one muscle fiber abuts on another, the membranes of both fibers 
parallel each other through an extensive series of folds. These areas, which 
always occur at Z lines, are called intercalated disks. They provide a strong 
union between fibers, maintaining cell to cell cohesion, so that the pull of one 
contractile unit can be transmitted along its axis to the next. Along the sides 
of the muscle fibers next to the disks, the cell membranes of adjacent fibers 
fuse for considerable distances, forming gap junctions. These junctions 
provide low resistance bridges for the spread of excitation from one fiber to 
another. They permit cardiac muscle to function as if it were a syncytium, 
even though no protoplasmic bridges are present between cells. The T system 
in cardiac muscles is located at the Z lines rather than at the A-1 junction, 
where it is located in mammalian skeletal muscle. 
ANATOMY AND PHYSIOLOGY OF LUNG 
Lungs are paired organs of respiration. They are situated one on each 
side of the mediastinum within the thoracic cavity.  
Shape: Each lung resembles a half cone. It has an apex, a base, 2 
surfaces- medial and lateral and 3 borders- anterior, inferior and posterior.  
Size: The right lung is broader than the left lung and weighs 22 ounce, 
whereas the left lung weighs 20 ounce. 
Each lung is covered by pleural cavity. The pleura is a completely 
close serous sac which is invaginated from the medial side by the developing 
lung and as a result of this invagination it is converted into a double layered 
sac. There is an outer layer and an inner layer. The outer layer is called the 
parietal layer which lines the inner walls of the cavity in which the lung lies. 
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It is divided into diaphragmatic pleura, costal pleura, cervical pleura and 
cervical pleura depending on the region which it lines. The inner layer also 
called the pulmonary pleura or the visceral pleura is very closely adherent to 
the surface of the lung, dips into its fissures and is responsible for the shiny 
appearance of the surface of the lung. Pleural cavity is a space between the 
two pleura which is filled with a thin fluid of lymph-like fluid, it lubricates 
and prevents friction during movements of the lung. 
Each bronchus on entering the hilum divides into branches which in 
turn divide repeatedly in the same manner. The tertiary branches are referred 
as the segmental bronchi. 
The bronchus and its division are closely accompanied by the 
pulmonary artery and its branches. Each segmental bronchus and the 
accompanying division of the pulmonary artery supply a definite part of the 
lung and the veins are not segmental, but are intersegmental in position and 
functions. The bronchopulmonary segments are functionally independent 
units and each unit is surrounded by connective tissue which is continuous 
with that the visceral pleura. 
Lung is supplied by pulmonary artery and bronchial artery and 
pulmonary and bronchial veins. The lymphatic drainage is via superficial and 
deep lymphatic system. Lung is supplied by anterior and posterior both 
sympathetic and para sympathetic pulmonary plexus.  
HISTOLOGY AND DEVELOPMENT 
Thin alveolar septae separate the alveolar spaces. The septae are lined 
by thin flattened alveolar cells with a capillary network of blood vessels on 
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their wall. Electron microscopic studies show that the blood in the capillaries  
and the air in the alveoli are separated by a thin continuous layer of the 
alveolar epithelium and capillary endothelium with two layers of the 
basement membrane in between them. Many alveolar cells are phagocytic. 
Each section of intrapulmonary bronchi will show (a) an outer fibrous 
coat with irregular plates of hyaline cartilage (b) middle bronchial muscles 
fibres and (c) inner mucous membrane which is headed by a layer of ciliated 
columnar epithelium, on its inner surface with lymphoid t issue, longitudinal 
elastic fibers and mucus secreting glands outer to the epithelium. 
The terminal or respiratory bronchioles are about 3.2mm in diameter 
and have cartilages in their walls. Simple nonciliated cubical epithelium lines 
their lumen. 
The respiratory passage first appears as a laryngotracheal groove in the 
floor of the primitive pharynx. The groove deepens, its margins fuse and a 
laryngotracheal tube is formed. Unfused cephalic end forms the inlet of the 
larynx. The caudal end of the tube divides and forms the lung buds. Each bud 
repeatedly divides dichotomously, 17 to 24 generations of divisions occur and 
these divisions form the alveoli respiratory bronchiole on the bronchi. The 
developing lung shows the four stages1. They are 
1) Pseudoglandular stage 
2) Canalicular stage 
3) Terminal sac stage 
4) Alveolar stage 
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The lining epithelia of the bronchi and alveoli are derived from the 
endoderm of the floor of pharynx. The connective tissue of the bronchi and 
the lung develop from the splanchnic mesoderm. 
FUNCTIONS OF THE LUNG 
Ventilation, oxygenation, diffusion of carbon dioxide, elimination of 
inspired particles via mucociliary system, synthesis of pulmonary surfactant 
activation of angiotensin I to angiotensin II,  inactivation of bradykinin, 
serotonin, histamine, acetylcholine, non adrenalin etc… and it act as a 
reservoir of blood.  
HISTORY OF INFLAMMATORY MYOSITIS 
The characteristic ‘heliotrope’ rash of dermatomyositis was recognized 
before the disease itself in 1875, in a 17 year old waiter in Paris, France, who 
presented with fatigue, pain in the extremities and erythema of the eyelids. 
Eleven years later, in 1886, Wagner coined the term ‘polymyositis’ he 
described a women presenting with muscle weakness and diffuse muscle and 
joint pain who developed swelling of the extremities and forearm erythema. 
In 1888, the first American case of polymyositis documented by muscle 
biopsy was reported in New York. Because trichinosis was common at that 
time and could cause periorbital edema and diffuse myalgias, it was necessary 
that polymyosit is or dermatomyosit is be a diagnosis of exclusion, requiring an 
incompatible dietary history and a muscle biopsy lacking Trichinella spiralis 
cysts. 
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In 1891, Univerricht described a 39 years old pregnant women with 
facial erythema and tense, swollen and erythematous legs and thighs who later 
delivered a healthy infant. She subsequently developed myalgias with muscle 
weakness and atrophy and Unverricht3 introduced the term ‘dermatomyositis’ 
to describe her condition. Although wagner and Univerricht are credited with 
the first descriptions of dermatomyositis,  Unverricht noted that Virchow may 
have initially recognized the clinical features. 
Steiner’s4 summary of myositis cases in 1903 made a clear distinction 
between idiopathic polymyosit is and other forms of myositis caused by 
bacteria and parasites, and Stertz in 1916 first reported an association 
between dermatomyositis and internal malignancy. At about the same time, 
Batten described the first case of dermatomyosit is with classic histologic 
features in a child. 
In 1930, Gottron reported on the skin lesions of dermatomyosit is that 
bear his name, describing rounded foci of tense atrophy over carpo-
metacarpal joints. 
The first published cases of dermatomyositis associated with 
carcinoma were independently reported in 1916 but Becezny, a Prague 
dermatologist, suggested a more definitive relationship between 
dermatomyosit is and cancer on 1935. 
Banker and Victor noted that dermatomyositis in children was 
different and involved a greater degree of vascular inflammation and 
thrombosis. More recently in 1967, the pathology of inclusion body myositis 
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was described and named in 1971. Prior to 1975 there were no generally 
accepted criteria for the diagnosis of myositis but Bohan and Peter proposed 
five criteria, in 1975 which are still used today. With the discovery of auto 
antibodies associated with the myositis syndromes, classification using 
serological features was later suggested. 
EPIDEMIOLOGY 
The actual annual incidence of inflammatory myopathy is currently 
unknown. Because these disease are so rare, no large scale epidemiologic 
studies have been reported however several retrospective studies5 have 
reported an annual incidence of fewer than 10 per million individuals.  
These incidence, prevalence studies need to be interpreted cautiously, 
given that most have not reported confidence intervals for their rates. 
The incidence of the various myopathies varies according to ethnicity, 
age and gender. Some studies have reported that the incidence of polymyositis 
is higher in black patients than in white patients. Idiopathic Inflammatory 
Myosit is (IIM) can occur in any age group from early childhood to late in 
adult life. The onset of polymyositis is usually in the late teens or older, with 
the mean age at onset being 50 to 60 years; dermatomyositis shows to peaks 5 
to 15 years and 45 to 65 years. Inclusion Body Myositis (IBM) is commonly 
seen in individuals older than 50 years and is rare in younger adults. In case 
of IIM (PM-DM) females are more commonly affected than males whereas in 
IBM the converse is true. 
IIM can occur in association with other autoimmune connective tissue 
diseases like Systemic Sclerosis, Systemic Lupus Erythematosus (SLE), 
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Rheumatoid Arthrit is (RA), Sjogren’s Syndrome, Poly Arterit is Nodosa 
(PAN), and around 11% to 40% of all myositis patients have an associated 
connective tissue disease6.  
CAUSE 
Genetic factors7 
The occurrence of IIM in monozygotic twins and first degree relatives 
of cases supports a genetic predisposition, at least in some families. HLA 
genes implicated are HLA-DRB1*0301, HLA-DQA1*0501, HLA-DQB1*0.01 
which are associated with polymyositis and myositis specific auto antibodies. 
In IBM, HLA B8, HLA DR3, HLA DR52, HLA DQ2 haplotype found 
in significant proportions. Some studies reported maternally derived chimeric  
cells are present in the peripheral blood and muscle tissue of juvenile  
dermatomyosit is patients, suggesting that HLA association found in these 
disorders.  
Non HLA genes implicated are Tumour Necrosis Factor- (TNF-),  
interleukin-1 (IL-1), and Tumour Necrosis Factor Receptor-1 (TNFR-1), 
Complement Component (eg. C4, C2), immunoglobulin heavy chain allotypes 
and T cell receptors.  
ENVIRONMENTAL RISK FACTORS 
Infectious organisms 
Polio, coxsackie virus8 type A and B, echoviruses, Retro viruses,  
HIV-I, HTLV-1, parvovirus B19, Hepatitis C Virus, Hepatitis C virus, 
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Hepatitis B virus, Staphylococci, Clostridia, Mycobacteria, 
Toxoplasmagondii, Tryponosoma Cruzi, Borrelia burgdogferi. 
Non infectious agents9 
Drugs like steroids, chloroquine, statins, biological agents.  
Vaccination for tetanus BCG, diphtheria, hepatitis B and A.  
UV radiation exposure. 
Miscellaneous agents like silicon breast implants, collagen injection, 
silica exposure, Chronic Graft Versus Host Disease (CVHD). Malignancy is 
an additional risk factor for the development of myosit is and there is a strong 
association between dermatomyositis and malignancies. 
PATHOGENESIS 
Immune and nonimmune pathways play a role in the disease 
pathogenesis. The magnitude and exact nature of the contribution of these 
pathways to disease initiation and progression are still unclear. Understanding 
the relative contribution of these pathways is important to design rational 
therapies for these disorder.  
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Mechanism of Muscle Fiber damage in Inflammatory Myositis 
ADAPTIVE IMMUNE MECHANISMS 
Inflammatory myopathies are classified as auto immune diseases10 
because of the following evidence.  
1) Patient shows antibodies to specific auto antigens. 
2) Presence of T cells in large infiltrates in muscle tissue. 
3) Strong association with HLA DR genotypes. 
4) Frequent association with other autoimmune diseases.  
5) Favourable response to immunosuppressive and immuno 
modulatory therapies in some patients supports that these 
myopathies are autoimmune diseases. 
HUMORAL IMMUNE RSPONSE 
 Up to 80% of the patients with polymyositis and dermatomyositis have 
positive antinuclear antibodies (ANA), some of these are specific to 
myositis and others not specific to but associated with myositis (anti-
SnRNP, anti-Ro/SSA, Anti-Ku, and anti-PMS1). 
 Some of these antibodies are associated with distinct clinical features 
of the disease (ex. anti-Mi-2, antibodies show very strong association 
with dermatomyositis with prominent features like gottron papules, 
heliotrophe rash, the V sign and shawl sign were as most frequent 
myositis specific autoantibodies the aminoacyl t-RNA synthatases 
associated with another distinct clinical entity named anti-synthatase 
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syndrome with features including mechanic hands11, Raynauds 
phenomenon, myositis, interstitial lung disease, non erosive arthritis.  
To date 8 different anti synthetase autoantibodies have been identified 
of which anti-histidyl-tRNA synthetase auto antibodies of the most  
frequent. The most common shared clinical features of these auto 
antibodies are occurrence of ILD. 
 The role of B cells12 in the pathogenesis of polymyositis and 
dermatomyosit is is supported by the presence of B cells and plasma 
cell infiltrates in the muscles tissue and scripts in the muscle tissue of 
patients with myositis. Analysis of the variable regions gene sequences 
revealed clear evidence of significant somatic mutation, isotypes 
switching, receptor revision, codon insertion/ deletion, and oligoclonal 
expansion, suggest ing that affinity maturation had occurred within the 
B-cell and plasma cell populations in the muscles tissue. Antigens 
localized to the muscle might drive a B-cell antigen specific response 
in myositis and these antigen could be autoantigens or exogenous cross 
reactive antigens derived from viruses or other infectious agents.  
 There is a differential organ expression of these antigens were by 
histidyl- t-RNA synthetase has higher expression in the epithelial cells 
of the bronchi than in other healthy organs, which might suggest that 
autoimmunity to this antigen is init iated and propagated in the lung. 
There is an upregulation of Mi2 antigens and histidyl t-RNA synthetase 
in the regenerating muscle fibers which suggest that muscle fibers may 
become potential targets of the immune system after trauma. There is 
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an abnormal modulation of the muscle environment which leads to 
muscle dysfunction.  
 Anti Jo-1 antibodies13 have a type-I interferon- inducing capacity, 
higher expression of intercellular adhesion molecules, microvascular 
endothelial cells of lungs activate and facilitate homing of inflammatory 
cells into tissues. There is also associated high serum levels of D-cell 
activating factor. 
CELL MEDIATED IMMUNE RESPONSE 
Two different pattern of distribution, location and type of lymphocyte 
subsets in the muscle tissue suggest ing two different pathways.  
1) CD4+ T lymphocytes, Macrophages, B-lymphocytes, Plasma cells and 
Dentritic cells predominantly in perivascular and perimysial areas of 
tissue which is mainly but not exclusively found in patient with 
dermatomyosit is.  
2) CD8 + T and CD4 +T lymphocytes, macrophages and dentritic cells 
predominantly in an endomysial distribut ion with inflammatory cells 
some times invading non necrotic muscle fibers. This pattern is found 
mainly in patients with myosit is without skin rash and polymyosits. 
3) Vascular involvement in patients with dermatomyositis c learly 
manifested in the skin can be clinically seen in the form of capillary 
nail fold changes. The capillary changes and damages are attributed to 
complement deposition. There is thickening, dropout, decrease in 
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number, hyperplasia and necrosis of the capillaries that could 
contribute to an ischaemia inturn to cause muscle fiber damage. 
4) Endomysial inflammatory infiltrates contain high percentage of 
activated CD 8+ T lymphocytes, CD 4+ T lymphocytes, macrophages 
and CD 28 null T cells with up regulation of perforin14 expressing 
cytotoxic T cells oriented towards the muscle fibers.   
INNATE AND NON IMMUNE MECHANISMS 
Effector molecules that are produced by muscle fibers, inflammatory 
cells and endothelial cells thought to contribute to the pathogenesis of 
myositis. Proinflammatory cytokines such as IL-1 Alpha, IL-1 Beta, TNF 
Alpha, Interferon Alpha and Beta, HMGB1 and chemokines like CXCL9, 
CXCL10 and the beta - chemokines CCL2, CCL3, CCL4, CCL4, CCL19 and 
CCL21 are present in the muscle tissue of patients with polymyositis and 
dermatomyosit is. These molecules may amplify the immune response, alter 
the muscle micro environment and causes direct muscle fiber dysfunction.  
 IL-1 alpha and HMGB-1 cytokines consistently found in patients with 
persisting muscle weakness, expression of mPGES-1 and COX-1 
remained unchanged, indicating a role of these enzymes in the 
chronicity of polymyosits and dermatomyositis. 
 Type-1 Interferon system has got an ability to break tolerance, and 
correlates with MHC class-I expression in the muscle fibers causing 
muscle dysfunction. 
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 HMGB115 protein is an ubiquitous nonhistone molecule present in all 
nucleated cells. Extranuclear HMGB1 may have proinflammatory 
properties and may also have a function in muscle cell regeneration 
HMGBI can induce  a reversible  upregulation of MHC class-I in the 
muscle fibers, may cause an irreversible decrease in Ca2+ release in the 
sarcoplasmic reticulum has a direct negative effect on muscle fiber 
contractility. Thus HMGB1 may be an early inducer of skeletal muscle 
dysfunction in inflammatory myosit is.  
 Hypoxic symptoms and muscle fatigue in patients with myosit is may 
be due to muscle tissue hypoxia, reduced level of energy substrates, 
acquired metabolic disturbances producing impaired performance. 
 MHC Class-1 expression and muscle fibers: MHC class-I molecules are  
known to play a critical role in initiating and perpetuating antigen-
specific immune responses by presenting antigenic peptides to CD8+ T 
lymphocytes and by regulating the activities of NK cells. 
 In normal differentiated skeletal muscle cells,  MHC class-I is either 
absent or expressed at low levels; however, they can be promptly 
induced by proinflammatory cytokines, for example interferon alpha or 
TNF alpha. 
 The mouse model16 of myositis suggested that MHC class-I molecules 
themselves may potentially mediate muscle fiber damage and 
dysfunction through innate and nonimmune mechanisms in the absence 
of lymphocytes, like attenuation of muscle regeneration and 
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differentiation, muscle atrophy and an intrinsic decrease in force 
generating capacity. 
 Over expression of MHC class-I muscle fibers of patients with 
myositis and the transgenic mouse model of myositis results in 
activation of the Nuclear Factor Kappa-B (NFB) and Endoplasmic 
Reticulum (ER) stress response pathways.  
 MHC class-I expression in the skeletal muscle links the classic immune 
and nonimmune mediated mechanisms of muscle impairment and 
damage. Altered redox state of sarcoplasmic reticulum leads to 
activation of unfolded protein response and myopathy in people with 
Hexose-6-Phosphate Dehydrogenase (H6PD) deficiency. 
IMMUNOLOGIC ABNORMALITIES IN PATIENTS WITH 
INFLAMMATORY MYOPATHIES 
Cellular Abnormalities 
T Cell receptor restriction in inflamed muscle 
Activated T and B lymphocytes expressing co-st imulatory molecules: 
CD86/ CD80 CD28/CTLA4; CD4O/CD4OL in skeletal muscle 
Increased peripheral mononuclear cell trafficking to muscle 
Increased proportions of peripheral T and B lymphocytes bearing 
activation markers 
Type I interferon gene expression in muscle t issue and peripheral 
blood of dermatomyositis and polymyositis patients 
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High expression of proinflammatory cytokines and chemokines in 
muscle tissues like IL-la, IL-1, TNF, HMGB-1, VEGF, MIP-I alpha) 
Elevated serum IL-la, IL-2, soluble lL-2 receptors and soluble CD8 
receptors 
Decreased proliferative responses of peripheral mononuclear cells to 
T-cell mitogens 
Increased proliferative responses of peripheral mononuclear cells to 
autologous muscle 
Increased expression of cytokines and chemokines in infiltrating 
mononuclear cells and muscle cells 
Increased expression of MHC class I (HLA-A,B,C), class II (HLA-
DR), and ICAM-l in skeletal muscle fibers. 
 
HUMORAL ABNORMALITIES IN MYOSITIS ARE 
 Immunoglobulin and complement deposition in vascular endothelium of muscle. 
 Myosit is-specific autoantibodies  
 Myosit is-associated autoantibodies (anti-Ui RNP, anti-PM/Sd, anti-Ku) 
 Other-autoantibodies (antithyroid, anti-Sm, anti-Ro, anti-La, etc.) 
 Hyper-, hypo-, and agammaglobulinemia 
 Monoclonal gammopathy 
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MUSCLE HISTOPATHOLOGY17 
Characteristic histopathologic signs in patients with inflammatory 
myopathies are presence of mononuclear inflammatory cell infiltrates in 
muscle tissue and degenerating, necrotic fibers, as well as regenerating 
muscle fibers. Atrophy of muscle fibers in a perifascicular fashion is mainly 
found in patients with dermatomyositis, often in a later phase of disease. In 
inclusion body myositis, rimmed vacuoles are characteristic features that can 
be seen in a light microscope nuclear or cytoplasmic inclusions are mainly 
detected by electron microscopy. None of these biopsy features is 
pathognomonic for myosit is but may also occur in other disorders, and they 
are not directly linked to muscle function. Importantly, these histopathologic 
features are often focal and in some cases a muscle biopsy can look normal 
despite clinically evident muscle weakness. Furthermore, the degree of 
histopathologic features is not correlated with the degree of muscle weakness. 
The focal feature of inflammation is also observed by magnetic resonance 
Imaging (MRI), which can detect inflammation as a bright signal using the 
Short Tau Inversion Recovery (STIR) sequence. The reasons for this 
heterogeneity of muscle inflammation are not known, but the heterogeneity 
suggests that not only does immune-mediated muscle fiber damage cause 
impaired muscle function but that other mechanisms are also important, as 
discussed next. 
IMMUNOPATHOLOGY 
Careful characterization of human muscle tissue from patients with 
myositis using immunohistochemistry has revealed that there is a tendency for 
different lymphocyte subsets to accumulate in different regions of the muscle, 
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suggest ing that there are different targets for the immune reaction. The 
pattern of distribution of inflammatory cells also tends to relate to different 
clinical subsets of myositis. 
 
Hematoxylin and eosin staining of muscle biopsy showing perivascular 
inflammation. A, Variation in fiber size and central nucleation (star). 
B, Endomysial inflammation and increased fibrosis. C, Perimysial 
inflammation (star). D, Perifascicular atrophy (arrow). 
Basically two different patterns of inflammatory cell infiltrates are 
found in muscle tissue of adult inflammatory myopathies. One is 
predominantly localized to the endomysium, composed mainly of CD8 and 
CD4 T cells, macrophages, and dendritic cells. In some cases the infiltrates 
surround and seem to invade non-necrotic muscle fibers. This feature is 
predominantly seen in polymyositis and inclusion body myositis. The other 
pattern has a perivascular and perimysial localization and is composed mainly 
of CD4 T cells, macrophages, dendrit ic cells, and B cells.  This is seen 
predominantly in dermatomyositis cases. These different immunohistopathologic 
features suggest that different pathogenic mechanism could be involved in the 
different subsets of myositis with a predominance of T cell-mediated muscle 
fiber damage in polymyosit is and inclusion body myositis and a role of the 
microvessel damage in dermatomyosit is. However, these changes are not  
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strictly related to presence or absence of skin rash. Moreover, in many 
patients the inflammatory cellular infiltrates are sparse and do not correlate to 
the degree of muscle symptoms, suggesting that other components of the 
immunopathology of inflamed muscle are also important for the disease. In 
contrast, the tissue distribut ion of signaling molecules produced in inflamed 
muscle t issues such as cytokines and chemokines does not seem to differ 
between subsets of myositis, indicating that some molecular mechanisms may 
be shared by different subsets of myositis. 
Another feature of inflammed muscle tissue is expression of MHC class I and 
II molecules in muscle fibers, which normally do not express these antigens MHC 
class I antigen expression is present in a majority of myositis patients both on 
regenerating fibers and on otherwise histopathologically normal-appearing muscle 
fibers. The MHC class I expression is localized to the muscle fiber membrane and 
often diffusely spread within the sarcoplasm. Furthermore, the MHC class I and class 
II expression on muscle fibers has been observed even in the absence of inflammatory 
cell infiltrates. The MHC class II molecules are less consistently expressed, mainly on 
scattered muscle fibers. The mechanisms by which MHC class I and class II 
expression are induced on muscle fibers in vivo have not been clarified, but from in 
vitro studies it has been demonstrated that proinflammatory cytokines or chemokines 
may induce MHC class I and class II expression on cultured muscle cells. These 
include cytokines that have been detected in inflammed muscle tissue such as IFN- 
and IL-la and 3, and TNF-. A possible role of the induced MHC class I on muscle 
fibers in the disease mechanisms of myositis is discussed previously. The MHC class 
I expression on muscle fibers, although not specific for myositis, could be helpful in 
diagnostic evaluation for distinction from normal muscle. 
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CLASSIFICATION OF INFLAMMATORY MYOSITIS 
DESCRIPTIONS 
 Pure polymyosit is (PM) 
 Pure dermatomyositis (DM) 
 Overlap myosit is (OM): myosit is with at least one clinical overlap 
feature or an overlap autoantibody 
 Cancer-associated myositis (CAM): clinical paraneoplastic features 
without an overlap autoantibody or anti-Mi-2 
BOHAN AND PETER DEFINITION OF MYOSITIS18 
1) Symmetric proximal muscle weakness 
2) Elevation of serum skeletal muscle enzymes 
3) Electromyographic triad of short, small, polyphasic motor unit  
potentials; fibrillations, positive sharp waves, and insertional 
irritability; and bizarre, high-frequency repetitive discharges 
4) Muscle biopsy abnormalities of degeneration, regeneration, necrosis, 
phagocytosis, and interstitial mononuclear infiltrate 
5) Typical skin rash of DM, including heliotrope rash, Gottron’s sign, and 
Gottron’s papules Definite myositis: 4 criteria (without the rash) for 
PM; 3 or 4 criteria (plus the rash) for DM Probable myositis: 3 criteria  
(without the rash) for PM; 2 criteria (plus the rash) for DM Possible  
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myositis: 2 criteria (without the rash) for PM; 1 criteria (plus the rash) 
for DM 
DEFINITION OF CLINICAL OVERLAP FEATURES 
Inflammatory myopathy plus at least one or more of the following 
clinical findings: polyarthritis, Raynaud’s phenomenon, sclerodactyly, 
scleroderma proximal to metacarphophalangeal joints, typical SSc-type 
calcinosis in the fingers, lower esophageal or small-bowel hypomotility, 
DLCO lower than 70% of normal predicted value, interstitial lung disease on 
chest radiograph or computed tomography scan, discoid lupus, anti- native 
DNA antibodies plus hypocomplementenemia, 4 or more of if American 
College of Rheumatology criteria for systemic lupus erythematosus, 
antiphospholipid syndrome. 
DEFINITION OF OVERLAP AUTOANTIBODIES 
Antisynthetases (Jo-1, PL-7, PL-12, OJ, EJ, KJ), scleroderma-
associated autoantibodies (scleroderma-specific antibodies: centromeres, 
topoisomerase I, RNA polymerases I or Ill, Th; and antibodies associated with 
scleroderma overlap: U1 -RNP, U2-RNP, U3-RNP, U5-RNP, Pm-SCL, Ku, 
and other autoantibodies (signal recognit ion particle, nucleoporins) 
DEFINITION OF CLINICAL PARANEOPLASTIC 
FEATURES 
Cancer within 3yrs of myosit is diagnosis, plus absence of multiple  
clinical overlap features; plus, if cancer was cured, myositis was cured as 
well. 
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CLINICAL FEATURES OF INFLAMMATORY 
MYOSITIS 
PRESENTATION 
The most frequent symptom is insidious progressive and painless 
symmetric proximal muscle weakness over the course of 3-6months before the 
first visit to a physician. The present features of the different myositis 
symptoms vary considerably from patient to patient.  
CONSTITUTIONAL  
Fever, weight loss, fatigue, loss of appetite. 
SKIN 
Gottron papules – violaceous flat-topped papules and plaques located 
over the dorsal aspect of interphalangeal or metacarpophalangeal joints. Over 
time, these papules may evolve and develop atrophic, depressed, white  
centers with prominent telangiectasias. 
Heliotrope rash19, periorbitaledema, Vsign, Shawlsign, Gottron sign, 
mechanichands, nail fold telengiectasias, cuticular over growth, periungual 
erythema, pleuritis, calcinosis. Rare findings like nonscarring alopecia, 
erythroderma, vesiculobullous lesion, leukocytoclastic vasculit is, and 
livedoreticularis, flagellate erythema, poikiloderma, digital ulcers, palpable 
purpura, urticaria like lesions, livedoreticularis, hyperkeratotic follicular 
erythematous papules (pityriasis rubra pilaris), cutaneous vasculitis. 
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CARDIAC MANIFESTATIONS 
Cardiac involvement in myosit is was first described by Oppenheimin20 
1899. Historically, it was believed that myosit is spared the heart. However, 
based on autopsy studies, it has become evident that cardiac involvement, 
although usually asymptomatic, is more common than previously believed21, 
Cardiac involvement is a major cause of mortality in patients with myositis.  
In a long-term follow-up study, cardiovascular involvement was found to be 
the most common cause of death in patients with myositis. 
The myocardium has been reported to be affected in patients with DM 
with varying frequencies. Up to 50% of patients with DM evaluated by 
noninvasive studies have asymptomatic cardiac manifestations. Noninvasive 
studies have shown that up to 85% of patients have abnormal findings on 
electrocardiography, 77% on ambulatory monitoring, 42% on 
echocardiography, and 15% on radionucleotide ventriculography. 
Cardiac manifestations included arrhythmia, conduction abnormalities, 
cardiac arrest, Congestive Heart Failure (CHF), myocarditis, pericarditis,  
angina, and secondary fibrosis. 
The frequency of cardiac involvement in myositis has been reported 
between 6% and 75%22. Cardiac involvement as a cause of death in PM has 
been reported between 10% and 20%, although this number is uncertain 
because large studies are unavailable. 
Conduction abnormalities are the most common asymptomatic cardiac 
manifestation, which are observed in 32% to 72% of patients. These 
abnormalit ies include ST-T changes, bundle branch block, atrioventricular 
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blocks, PR prolongation, Q-wave abnormalities, and arrhythmias. In some 
cases, patients require pacemaker placement. 
Arrhythmias and Congestive Heart Failure (CHF) secondary to 
myocarditis rarely occur in patients with acute disease. In chronic DM, heart 
failure is seen more frequently and is the most common symptomatic  
manifestation. The frequency of CHF has been reported to be 3% to 45% in 
patients with myositis. In chronic DM, heart failure has been attributed to the 
effects of long-standing hypertension secondary to steroid use. It has also 
been theorized that the cause of CHF is secondary to myocarditis, leading to 
left ventricular dysfunction and restrictive cardiomyopathy, or possibly 
because of fibrosis, resulting in chamber st iffness. It is thought that 
myocardial involvement  resulting in myocarditis occurs by the same 
mechanism that results in skeletal muscle involvement. Mononuclear 
inflammatory cells infiltrate into the endomysium and peri-vascular areas, 
resulting in degeneration of cardiac myocytes. Histopathologic changes 
similar to those in the myocardium were also observed in the conduction 
system, which could explain the cause of heart block. 
Angina secondary to Raynaud phenomenon, Prinzmetal angina, and 
small vessel disease has also been reported in patients with DM. Pericardial 
tamponade is very rare, with a frequency reported at about 10%. However, 
because tamponade can be fatal, electrocardiography of every case is 
recommended. Clinically symptomatic cardiac involvement is uncommon, and 
when present, it is associated with a poor prognosis. 
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There have also been reported associations between cardiac 
involvement and anti - signal recognition particle (SRP) antibodies. However, 
more recent evidence suggests that anti-SRP antibodies may not contribute to 
cardiac involvement to the degree that was once suspected. 
PULMONARY MANIFESTATIONS 
Pulmonary complications are a major cause of morbidity and mortality 
in patients with PM and DM. These complications occur primarily or 
secondarily due to muscle weakness. Three distinct pulmonary complications 
of PM and DM have been described: hypoventilation, aspiration pneumonia, and ILD. 
Respiratory failure due to hypoventilation has been historically thought  
to be a rare complication reported in less than 5% of patients with myositis.  
However, a more recent, larger, retrospective study of patients with DM and 
PM reported a higher prevalence of Hypoventilation occurs in patients with 
severe muscle weakness and inflammation, involving respiratory muscles. As 
a result, restrictive lung function impairment is noted on pulmonary function 
tests (PFTs). Patients are noted to have reduced lung volumes and maximal 
inspiratory and expiratory pressures, along with increased residual volumes 
and normal forced expiratory volume in the end of the first second of forced 
expiration to forced vital capacity (FVC) ratio. Chest radiographs reveal small 
lung volumes and basal atelectasis. 
Aspiration pneumonia is a frequent complication of PM and DM, 
occurring in approximately 17% of patients. Patients suffering from aspiration 
pneumonia also frequently complain of dysphagia, which results from disease 
involvement of the striated muscles of the pharynx and upper esophagus. 
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Aspiration pneumonia is more likely to occur in patients with more extensive 
muscle and skin disease. 
ILD is an inflammatory lung disorder of unknown cause, characterized 
by infiltrates of monocytes, lymphocytes, and neutrophils, as well as 
interstitial fibrosis. ILD is a common complication in PM and DM. The 
incidence of ILD has been reported between 5% and 46% in cross-sectional 
studies23. No significant difference in the prevalence of ILD exists between 
patients with PM and DM. ILD associated with myositis may occur before, 
concomitantly, or after the onset of skin or muscle symptoms. ILD associated 
with Amyopathic Dermatomyosit is (ADM) is a dist inct subset in which the 
lung disease is rapidly progressive. 
Myosit is-associated ILD occurs in 3 different patterns: (1) acute onset 
of symptoms, in which patients develop apparent progressive hypoxemia 
within a month of lung involvement; (2) chronic slowly progressive 
symptoms; and (3) asymptomatic progression, in which ILD is demonstrated 
only by abnormal results of chest imaging or PFT. 
Cough and dyspnea are the most frequently reported symptoms in ILD, 
although patients can be asymptomatic. In one study, 27% of patients with 
ILD were asymptomatic24. Pulmonary Function Tests (PFT) demonstrate a 
restrictive ventilatory impairment and can show decreased total lung capacity, 
functional residual capacity, residual volume, FEV1, and FVC, with a normal 
or elevated FEV1/FVC ratio and reduced diffusing capacity of lung for carbon 
monoxide. 
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Although chest radiography is a useful screening test, High-Resolut ion 
Computed Tomography (HRCT) of the lungs is the standard technique for 
detecting ILD. HRCT is thought to be useful in distinguishing fibrotic disease 
from active inflammation, with the former presenting as a reticular pattern 
and the latter as ground-glass pattern. 
Bronchoalveolar Lavage (BAL) is not specific for the diagnosis of 
Interstitial Lung Disease (ILD), although it is useful in differentiating 
pulmonary symptoms, such as evaluating for infection, drug-induced reaction, 
and malignancy25. However, similar to idiopathic pulmonary fibrosis, 
neutrophil-predominant alveolitis and increased eosinophil counts may 
indicate more progressive disease. Lung biopsy is not routinely performed for 
diagnosis because of the increased morbidity associated with the procedure. 
Most frequently seen HRCT changes are those of idiopathic 
nonspecific interstit ial pneumonia (NSIP), with irregular linear opacities and 
with areas of consolidation and ground-glass pattern. However, other patterns 
such as usual interstit ial pneumonia, bronchiolitis obliterans with organizing 
pneumonia, and diffuse alveolar damage (DAD) are also seen. 
The presence of antiaminoacyl-transfer RNA (tRNA) synthetase 
antibodies, of which antihist idyl- tRNA synthetase antibody (anti-Jo-1) is 
most frequently found, is the strongest predictive marker for ILD.” The 
prevalence of ILD with anti- Jo-1 antibodies is more than 70%. There are also 
other markers for ILD, including PM-Scl autoantibodies, Krebsvonden 
Lungen 6, a glycoprotein expressed on type 2 alveolar pneumocytes and 
bronchiolar epithelial cells, and serum surfactant protein D have been 
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suggested as useful markers for ILD in patients with myosit is. However, these 
markers are not routinely used in clinical practice. Serum cytokeratin (CK) 19 
fragment, a component of bronchoepithelial cells, is also associated with ILD 
in myositis. Patients with DAD have higher levels of CK-19 than patients 
with NSIP. 
ILD is considered a major risk factor for premature death. It is unclear 
if the prognosis of ILD in patients with PM is different from those with DM. 
However, one study showed that patients with DM-associated ILD were less 
responsive to steroid therapy than those with PM-associated ILD. 
Spontaneous pneumomediastinum has also been reported as a rare 
complication of myosit is-associated ILD, occurring with a prevalence of 8.3% 
in patients with PM and DM. Pneumomediastinum usually results from 
rupture of subpleural or paracardial blebs in ILD. In a recent retrospective 
study, most cases of pneumomediastinum occurred in patients with DM or 
ADM. Poor survival was associated with an absence of muscle weakness and 
severe pulmonary involvement before the onset of pneumomediastinum. 
Because of the concomitant use of immunosuppressive drugs in the 
treatment of inflammatory myopathies infections are another complication to 
be considered, particularly opportunistic infections. Bronchoalveolar lavage is 
a useful tool in making the diagnosis. 
SKELETAL MUSCLE 
The myositis patient complain of difficulty in performing activit ies 
requiring normal upper or lower limb strength. The onset is insidious, 
bilateral, symmetrical and patients, with involvement of proximal more than 
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distal muscles. An exception is IBM, in which asymmetric distal weakness 
and atrophy are as prominent as proximal muscle findings. Lower extremity is 
often affected initially, followed by upper extremity, neck flexor weakness. 
Patient may have proximal dysphagia with nasal regurgitation of liquids and 
pulmonary aspiration is a poor prognostic sign seen with severe disease. 
There will be reduction in aerobic and anaerobic capacity of muscle. Ocular 
or facial muscle weakness is uncommon.  
JOINTS  
Polyarthralgia, polyarthritis are relatively mild. Joint findings are more 
common with overlap and anti-synthatase syndrome.  
GASTROINTESTINAL TRACT 
Patient will have pharyngeal muscle weakness which result in 
dysphonia, difficulty in init iation of deglut ition26 or nasal regurgitation of 
liquids. If severe, aspiration of oral contents will occur. Patient may have 
retrosternal sticking sensation on swallowing bread or meat and heartburn. 
Patient may have small bowel involvement in the form of bloating, distension, 
watery diarrhea. GI ulceration can occur. Other manifestations are ascitis,  
total gut failure, pneumatosis cystoides intestinalis. 
VASCULAR SYSTEM INVOLVEMENT 
Patient may have Raynauds phenomenon, tender dermal subcutaneous 
nodules, periungual infarcts and digital ulcerations. 
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RENAL INVOLVEMENT 
Renal disease is unusual in myosit is, but there are reports of (IgA) 
nephropathy, membranous nephropathy, rhabdomyolysis with renal failure, 
Acute Tubular Necrosis (ATN) with renal failure due to myoglobinuria is also 
reported.  
MISCELLANEOUS 
People may have macroglossia, dental caries, hyposalivation, 
retinopathy or retinal vasculitis, subcutaneous edema, hemophagocytic 
syndrome, it is rarely associated with thyroid disorders, CNS vasculitis,  
progressive multifocal leukoencephalopathy. 
OVERLAP SYNDROMES 
Overlap syndromes associated with idiopathic inflammatory mysoitis 
are SLE, systemic sclerosis, MCTD, Rheumatoid arthrit is etc… 
INVESTIGATIONS 
 Complete blood count (Hb, TC, DC, ESR) 
 Liver function test (SGOT, SGPT, Bilirubin) 
 Renal Function Test (Blood Urea, Serum Creatinine) 
 Urine routine examination 
 Serum muscle enzymes (CPK, Aldolase, aspartrate, alanine amino 
transferases and lactate dehydrogenase) 
o Muscle Enzymes: Enzymes that leak from the injured muscle into 
the serum are valuable aids in detecting ongoing muscle injury. 
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Elevated CK and ALT provide evidence that ALT elevation may be 
of muscle origin than hepatic origin. 
o Serum CK is the most reliable enzyme test to use in routine patients 
care and predicts clinical events. During a flare of disease, the 
serum CK will usually increase weeks before over muscle weakness 
develops. There is an ethnic difference in the rise of serum muscle 
enzymes following myositis.  
o Measurement of urinary levels of muscle damage markers like 
creatine, betain and citrate, may be useful.  
ELECTORMYOGRAPHY (EMG) 
Electrical testing27 is a sensitive but non specific method of evaluating 
muscle inflammation. EMG may be helpful to diagnose myositis in the 
circumstance of normal serum enzyme concentration and the physical 
examination of muscle strength that is difficult to interpret. 
EMG findings suggestive of myopathic pattern are irritability of 
myofibrils at rest, positive sharp waves, short, low amplitude, polyphasic, 
potentials, complex repetitive discharges, loss of spontaneous activity, 
fibrillary waves etc. 
MUSCLE BIOPSY 
Biopsy remains the gold standard for confirmation of the diagnosis of 
inflammatory myopathy. Some patients with active myosit is have a normal 
biopsy for several reasons like wrong muscle, patchy disease and wrong 
technique. Various techniques available are open surgical biopsy, 
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percutaneous needle muscle biopsy. Open muscle biopsy is preferred over the 
needle biopsy because its provides a larger sample. Ideally we have to select a 
moderately weak muscle which is often best located by EMG testing of the 
contralateral side in combination with magnetic resonance imaging guided 
biopsy to provide the highest degree of accuracy. The characteristics findings 
are regeneration and degeneration of myofibrils, chronic inflammatory cells 
in the perivascular and interstitia l areas surrounding myofibrils are present in 
80% of cases, but lymphocytic invasion of non necrotic fibers is considered 
pathognomonic of polymyositis. Besides lymphocytes, other cells may be 
present, including hist iocytes, plasma cells, eosinophils, and 
polymorphonuclear leukocytes. In chronic myositis, macrophages are seen 
phagocytosing necrotic fibers and muscle is replaced by fibrous connective 
tissue or fat. 
In dermatomyositis B cells, T cells mostly CD8+ predominate in the 
perivascular area. CD4+Tcells are also found. Perifascicular myofibril 
atrophy, endothelial cell hyperplasia of blood vessels, deposition of immune 
complexes in the vasculature, muscle capillary depletion and dropout may be 
seen. In contrast, the polymyosit is T cell invasion of myofibrils with relative 
sparing of the perimysial areas but unlike DM, B cells are rarely observed. 
SERUM ANTIBODIES 
1) ENA Profile, ANA by ELISA, ANA by Hep 2 
2) Autoantibodies in IIM  
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AUTO ANTIBODIES IN IIM 
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HRCT LUNG 
The chest radiograph is insensitive in the diagnosis of ILD. HRCT scan 
using 1mm slices will have a better resolution and will assist in the early 
diagnosis of lung changes in IIM. HRCT findings consist with the 
inflammation include ground glass opacities, nodules and consolidation while  
features more consistent with fibrosis and damage include traction 
bronchiectasis and honeycombing. Subpleural lines or bands and linear 
opacities are not definitely associated with either inflammation or fibrosis. 
PULMONARY FUNCTION TEST 
Broncho Alveolar Lavage 
Instillation of 120ml of saline into distal a irspaces through the wedged 
bronchoscope and then aspired through the instrument’s suction channel. 
Fluid collected is subjected to microbiology testing, specific cytologic 
analysis and cell counts and other parameters. BAL is not specific for the 
diagnosis of ILD, although it is useful in differentiating pulmonary 
symptoms, such as evaluating for infection, drug-induced reaction, and 
malignancy. In inflammatory myosit is with ILD contains predominantly 
lymphocytes, neutrophils and eosinophils are high in severe progressive 
disease.  
PULMONARY FUNCTION TEST 
Pulmonary function tests are used to asses the disorders of lung. Cough 
and dyspnea are the most frequently reported symptoms in ILD, although 
patients can be asymptomatic. In one study, 27% of patients with ILD were 
asymptomatic PFTs demonstrate a restrictive ventilatory impairment and can 
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show decreased total lung capacity, functional residual capacity, residual 
volume, FEV1, and FVC, with a normal or elevated FEV1/FVC ratio and 
reduced diffusing capacity of lung for carbon monoxide. 
ELECTROCARDIOGRAM 
In inflammatory myositis common ECG abnormalit ies are non 
specified ST T wave changes, conduction abnormalit ies etc… 
ECHOCARDIOGRAM 
To diagnose cardiac involvement like valvular abnormalit ies, serositis,  
LV dysfunction etc.,  
Other imaging modalities are Doppler, MRI Imaging of muscles to 
look for muscle inflammation. 
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MATERIALS AND METHODS 
The study was conducted in the Department of Rheumatology, Madras 
Medical College, Chennai-3 from February 2011 to January 2012, after 
ethical committee clearance. Total number of patients included in the study is 
50 who fulfills inclusion criteria. All these patients were subjected to clinical 
examination, CBC, RFT, LFT, CRP, RF, Muscle enzymes (CPK, LDH, 
SGOT, SGPT) ECG, ECHO, PFT, HRCTLung, CXR, Broncho Alveolar 
Lavage (BAL), auto antibody profile (ANA, ENA Profile), muscle biopsy, 
ultra sound abdomen and EMG studies. 
STUDY DESIGN: CROSS SECTIONAL STUDY 
INCLUSION CRITERIA 
1) Patients fulfilling Bohan & Peter criteria for idiopathic inflammatory myositis. 
2) Patients with overlap syndromes presenting with inflammatory myositis. 
EXCLUSION CRITERIA 
1) Features of congenital myopathy 
2) Features of metabolic myopathy 
3) Features of Drug induced myopathy 
4) Features of Endocrine myopathy 
5) Features of muscular dystrophy 
6) H/o. Pulmonary TB in the past 
7) H/o. Diabetes Mellitus 
8) H/o. Exposure to irradiation to body 
CONFLICT OF INTEREST: Nil 
STATISTICAL METHOD USED: SPSS V-19 (Statistical Package for 
       Social Sciences) & Manual 
FUNDING AGENCY : Nil 
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OBSERVATION AND RESULTS OF THE DATA 
 
Table-1: Sex wise distribution of the Patients  
Sex No. of Patients (n=50) Percentage (%) 
Females 34 68 
Males 8 16 
Female Children 5 10 
Male Children 3 6 
 
Fig-1: Sex wise distribution of the Patients 
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Table-2: Age wise distribution of Adult cases 
Female Male 
Age in 
years No. of 
Patients 
(n=34) 
Percentage 
(%) 
No. of Patients 
(n=8) 
Percentage 
(%) 
17-25 years 8 23.5 0 0 
26-35 years 10 29.5 2 25 
36-45 years 8 23.5 4 50 
46-55 years 6 17.5 0 0 
56-65 years 0 0 2 25 
66-75 years 2 6 0 0 
 
Fig-2: Age wise distribution of Adult cases 
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Table-3: Age wise distribution of Paediatric cases 
Female Male  
Age in years 
No. of Patients 
(n=5) 
Percentage 
(%) 
No. of Patients 
(n=3) 
Percentage 
(%) 
1-5 years 0 0 0 0 
6-10 years 1 20 1 33 
11-16 years 4 80 2 67 
 
Fig-3:Age wise distribution of Paediatric cases 
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Table-4: Mean age of the patients at the time of presentation 
Sex No. of Patients (n=50) Mean age in Years 
Females 34 33.91 
Males 8 43.12  
Female Children 5 13.6 
Male Children 3 9.3 
 
Fig -4: Mean age of the patients at the time of presentation 
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Table-5: Mean duration of illness at the time of presentation in 
months 
Sex No. of Patients (n=50) 
Mean duration of illness in 
months 
Females 34 17.8 
Males 8 10.62 
Female Children 5 27 
Male Children 3 24 
 
Fig-5: Mean duration of illness at the time of presentation in months 
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Table-6: Disease Distribution among the study subjects 
Diseases 
No. of 
Patients 
(n=50) 
Percentage 
(%) 
Overlap Myositis (SLE, MCTD, Systemic 
Sclerosis, Childhood overlap) 
30 60 
Dermatomyositis 11 22 
Polymyositis 3 6 
Juvenile Dermatomyositis 5 10 
Juvenile Polymyositis 1 2 
 
Fig-6: Disease Distribution among the study subjects 
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Table-7: Frequency of myositis in overlap syndromes  
Overlap syndromes No. of Patients (n=31) Percentage (%) 
SLE myosit is overlap 20 65 
Systemic Sclerosis myosit is overlap 5 16 
MCTD Myositis overlap 4 13 
Childhood myositis overlap 2 6 
 
Fig-7: In overlap myositis frequency of various overlap syndromes 
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Table-8: ANA positivity in patients with inflammatory myositis 
ANA by ELISA and Hep 2 IIF was done to all the 50 patients. 
Adults Children 
ANA positivity by No. of 
Patients 
(n=42) 
Percentage 
(%) 
No. of 
Patients 
(n=8) 
Percentage 
(%) 
ELISA 35 83.33 5 62.5 
Hep-2 IIF 36 85.71 5 62.5 
 
Table-9: ANA pattern by IIF in adults and children 
Adults Children 
ANA pattern No. of 
Patients 
(n=36) 
Percentage 
(%) 
No. of 
Patients 
(n=5) 
Percentage 
(%) 
Speckled 20 55.55 3 60 
Homogenous 12 33.33 2 40 
Rim Pattern 2 5.55 0 0 
Nucleolar 2 5.55 0 0 
Fig -8: ANA pattern by IIF in adults and children 
55.55%
33.33%
5.55% 5.55%
60%
40%
0% 0%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Speckled Homogenous Rim Pattern Nucleolar
Adults Children
 
   
 58 
Table-10: ENA Profile 
It was done to 50 patients out of which 6 (12%) are positive for 
antibodies and no children is positive for ENA profile. 
Antibodies  No. of patients (n=6) Percentage (%) 
U1 RNP 4 66.66 
PMSCL70 1 33.33 
Jo1 1 33.33 
 
Fig-9: ENA Profile 
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SERUM MUSCLE ENZYMES ABNORMALITIES IN 
INFLAMMATORY MYOSITIS 
Table-11: Muscle Enzyme Elevation 
Enzymes No. of Patients Elevated (n=50) Percentage (%) 
CPK 36 72 
LDH 37 74 
SGOT 34 68 
SGPT 27 54 
All enzyme elevation 20 40 
 
Fig-10: Muscle Enzyme Elevation 
72% 74%
68%
54%
40%
0%
10%
20%
30%
40%
50%
60%
70%
80%
CPK LDH SGOT SGPT All enzyme
elevation
 
   
 60 
Table-12: Chest X-Ray abnormalities 
We have done to all the 50 patients Chest X-Ray PA view. Out of 50 
patients, 9(18%) showed radiological abnormalities. 
Chest X-ray findings No. of patients (n=9) Percentage 
Lung infiltrations 5 55.5 
Cardiomegaly 3 33.5 
Pleural Effusion 1 11 
 
Fig-11: Chest X-Ray abnormalities 
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LUNG ABNORMALITIES  
HRCT lung  
HRCT lung was done in 42 cases. HRCT lung involvement in the form 
of interstitia l infiltrates, Non Specific Interstitia l Pneumonit is (NSIP), Usual 
Interstitial Pneumonit is (UIP), nodular, reticular patterns, ground glass 
opacities and traction bronchiectasis were seen in 21(50%) out of 42 patients.  
In our study, various patterns of lung involvement in inflammatory 
myositis are 
1) NSIP (Non specific interstitia l Pneumonitis) characterized by reticular 
and or ground glass opacities with or without consolidation are seen in 
15 (71%) out of 21 patients. 
2) Honey combing, bronchiectatic changes with fibrosis seen in 4 (19%) 
patients out of 21. 
3) UIP (Usual Interstitial Pneumonia) 2 (9.5%) patients out of 21. 
4) Cryptogenic organizing pneumonia, diffuse alveolar damage were not 
seen in our study. 
5) Pleural effusion with consolidation was seen in 1 case of SLE myositis 
overlap. 
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HRCT Lung showing ground glass opacity in ILD  
-A case of dermatomyositis 
Fig-12: HRCT Lung 
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Table-13: Pulmonary function test abnormalities in inflammatory 
myositis 
Pulmonary function test were done in 42 (84%) patients out of 50.  
Pattern 
No. of 
patients 
(n=42) 
Percentage 
(%) 
Restrictive flow pattern (FEV1/FVC Normal or 
increased) 
16 38 
Restrictive and obstructive pattern (reduced 
FEV1, FVC, FEV1/FVC) 
3 7 
Poor Flow 4 9.5 
Normal PFT  19 45.5 
OP- Obstructive Pattern (Reduced FEV1/ FVC <0.7. 
 
Fig-13: Pulmonary function test abnormalities in inflammatory 
myositis 
45.50%
38%
9.50% 7%
0%
10%
20%
30%
40%
50%
60%
Normal PFT Restrictive flow
pattern
Poor Flow Restrictive and
obstructive pattern
 
   
 64 
Broncho Alveolar Lavage (BAL) abnormalities in inflammatory 
myositis 
BAL was done in 40 cases, children were excluded from the BAL and 
2 patients are not willing for BAL. The BAL was done under local anaesthesia  
with inst illation of 100ml of normal saline via flexible bronchoscope and 
subsequently aspirated via cannula. The aspirated fluid was subjected to cell 
count, grams stain, AFB smear and culture. In out study, inflammatory cells 
predominantly lymphocytes, neutrophils and eosinophils are seen in the smear 
around 23 cases. 2 cases of normal HRCT lung showed inflammatory cells.  
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Cardiac manifestations in inflammatory myositis 
Clinically significant cardiac dysfunction is uncommon in idiopathic  
inflammatory myosit is. But it is common in overlap myosit is. 
Table-14: ECG changes in inflammatory myositis 
ECG Changes No. of patients (n=50) 
Percentage 
(%) 
Normal ECG 24 48 
Non specific ST-T wave changes 22 44 
Juvenile T wave pattern 2 4 
P Pulmonale 1 2 
Low voltage complex 1 2 
Fig-14: ECG changes in inflammatory myositis 
48%
44%
4%
2%
2%
0% 10% 20% 30% 40% 50% 60%
Normal ECG
Non specific ST-T wave
changes
Juvenile T wave pattern
P Pulmonale
Low voltage complex
 
   
 66 
Table-15: Echo Cardiogram  
Out of 50 patients, cardiac manifestations were seen in 11 (22%) cases. 
These are the following abnormalities seen in our study 
Abnormalities No. of Patients (N=11) 
Percentage 
(%) 
Mitral regurgitation (mild) 3 27 
Percaridal Effusion seen Echo 3 27 
Aortic regurgitation (mild) 1 9 
Mild tricuspid regurgitation 1 9 
LV dysfunction 1 9 
Left ventricular hypertrophy 1 9 
RA, RV dilated with PHT 1 9 
Fig-15: Echo Cardiogram 
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Electormyographic Abnormalities 
EMG was done to all the 50 cases in our study, patients showing 
myopathic pattern (Short, sharp, low amplitude, positive, polyphasic, 
fibrillary waves, insertional irritability and spontaneous activity seen in 39 
(78%) out of 50 patients). 
Out of 50 patients, 78.57% were adults and 75% were children. 
Fig -16: Electormyographic Abnormalities 
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Muscle Biopsy 
In our study we have done open surgical biopsy of the vastus lateralis 
of thigh muscles and subjected to histopathological examination. Muscle 
biopsy done in 46 (92%) out of 50 patients. 
Out study shows 18 (39%) cases having histopathological evidence of 
myositis like inflammatory cell infiltration, focal areas of degeneration and 
regeneration, muscle fiber atrophy as well as perimysial inflammation. 
 
A case of dermatomyositis muscle biopsy report showing inflammatory 
cell infiltration by light microscopy using eosin and haematoxylin 
stain 
Fig-17: Muscle Biopsy Abnormalities 
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Table-16: Inflammatory Markers 
Inflammatory Markers 
No. of Patients 
(n=50) 
Percentage 
(%) 
CRP Elevated (Normal <6mg/dl) 31 62 
ESR Elevated  (Normal <20mm/hr) 30 60 
 
Fig-18: Inflammatory Markers 
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Table-17: Cutaneous features of dermatomyositis  
Adults Children 
Cutaneous Features No. of 
Patients 
(n=11) 
Percentage 
(%) 
No. of 
Patients 
(n=5) 
Percentage 
(%) 
Periorbital edema 8 72.7 5 100 
Heliotrophe Rash 6 54.5 4 70 
Malar Rash 3 27.2 0 0 
V Sign 1 9 0 0 
Shawl Sign 2 18.1 0 0 
Mechanic Hands 1 9 0 0 
Calcinosis 1 9 4 80 
Diffuse Erythema 1 9 1 20 
Raynaud’s Phenomenon 3 27.2 0 0 
Vasculit is Lesions 1 9 2 40 
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DISCUSSION 
Inflammatory myopathies are a heterogenous group of autoimmune 
disorders predominantly affecting skeletal muscles resulting in muscle 
inflammation and weakness. Along with musculoskeletal manifestations, 
involvement of other organ systems like skin, cardiac, gastrointestinal and 
pulmonary are common. In inflammatory myositis cardiac and pulmonary 
involvement results in significant morbidity and mortality. 
A South Indian study30 showed ILD in 9.2%, conduction disturbances 
1.15%, myocarditis 4.6%, muscle enzymes elevation 85.1%, myopathic  
pattern EMG 66.6%, muscle biopsy suggestive of myositis 85.29%, ANA 
positivity 67.24%. 
In our study, we aimed to study the various cardio-pulmonary 
manifestation in inflammatory myositis. In our study we included 50 patient  
who fulfilled inclusion criteria for inflammatory myositis after written 
consent and ethical committee approval for the period of one year (February 
2011 to February 2012). We subjected these patients to clinical examination, 
CBC, LFT, RFT, CXR, HRCT Lung, PFT, BAL, ECG, ECHO, Muscle Biopsy 
and EMG. 
In our study, total number of patients are 50. Out of 50 patients 34 
(68%) were females, 8(16%) were males, 5 (10%) were female children, and 
3(6%) were male children. 
In our study, mean age was for females (33.9 years), males (43.12 
years), male children (9.3 years), female children (15.6 years) with mean 
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disease duration in females (17.84 months), males (10.62 months), male 
children (24 months) and female children (24 months). 
Compared to Western studies, the most common type of inflammatory 
myositis is overlap (60-70%). In our study, the prevalence of overlap myositis 
is around 60%. Like other previous studies in our study polymyosit is is rare. 
There are variations in age at presentations. Inflammatory myositis is most  
common in females and polymyosit is is rare in children. 
In our study, among the overlap myositis, the SLE myositis overlap is 
most common (65%). In the decreasing order of frequencies systemic 
sclerosis myositis overlap (16%) MCTD myosit is ovelap (13%) and childhood 
myositis overlap (6%). 
Serum autoantibodies are commonly found in inflammatory myositis 
and useful in defining a subject of patients phenotypically. It may be myositis 
specific autoantibodies (5% to 30%) and myositis associated auto antibodies 
(10% to 40%). ANA positivity in our adult patients are around by ELISA 
(83.33%) and HEP2 (85.71%). Predominant pattern is speckled (55%) in 
adults. Other autoantibodies posit ive in our study are anti-U1 RNP, anti-
PMSCL, anti-Jo1. 
Enzymes that release from injured skeletal muscle into the serum is 
valuable in detecting ongoing muscle inflammation response to therapy to 
certain extent and flare of the disease. In our study CPK (72%), Lactate 
dehydrogenase (74%), SGOT (68%), SGPT (54%) were measured in all 
patients and found to be elevated in (67%) and helped in the classification and 
diagnosis of myosit is. 
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PULMONARY ABNORMALITIES 
Pulmonary involvement is a major cause of morbidity and mortality in 
patients with inflammatory myositis. We have done clinical examination, CXR, 
HRCT Lung, PFT and BAL to find out the frequency of pulmonary abnormalitits 
in our study. In our study, we have done chest X ray PA view to all patients. Out 
of 50 patients 9 showed abnormalities, in which 5 (55.5%) patients showed lung 
infiltration and 1 (11%) patients showed pleural effusion. 
We have done HRCT lung to 42 patients since ILD is uncommon in 
JDM. We have excluded childhood myositis cases from HRCT Lung. In our 
study, we found out 21 (50%) patients, out of 42 patients shown various 
forms of ILD, the most common pattern being NSIP in 71%, Honey combing, 
bronchiecctatic changes with fibrosis in 19%, least being UIP pattern. 
Compared to Western studies we have only 50% of ILD in myositis patients. 
It may be due to more overlap myosit is especially SLE myositis overlap 
(65%), usually in SLE around (14% to 43%) have lung involvement. In our 
study we findout again that HRCT lung is more sensitive in the diagnosis of 
pulmonary complications than Chest X-ray. 
We have done PFT to 42 patients, children were excluded due to 
technical difficulties in performing PFT in children. We have found out 
abnormalit ies in around 54.5% in which predominant abnormalit ies are 
restrictive flow pattern with (normal or increased FEV1/ FVC) and poor flow 
in 9.5% due to severe muscle weakness. 
In our study we have done BAL in 40 (80%) patients out of 50, 10 
were excluded from the BAL study in which 57.5% of the patients showed 
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inflammatory cells in the BAL fluid. In 21 patients with HRCT proven ILD 
showed inflammatory changes. So there is no need to do rout ine BAL in all 
cases of inflammatory myositis to diagnose pulmonary involvement. 
CARDIAC ABNORMALITIES IN INFLAMMATORY 
MYOSITIS 
Clinically significant cardiac dysfunction is uncommon in idiopathic  
inflammatory myosit is. But it is common in overlap myositis. We have done 
ECG and Echo cardiogram to all patients. Like other Western study22, the 
most common abnormality detected was non specific ST T-wave changes in 
around 44% in ECG. In Chest X ray around 33.5% had cardiomegaly. 
By echocardiogram 27% of patients, have Mitral Regurgitation (Mild) 
and Pericardial Effusion and other lesions diagnosed by echo are Aortic 
Regurgitation, Tricuspid Regurgitation, LV dysfunction, Left Ventricular 
Hypertrophy, RA, RV dilated with pulmonary hypertension. We have to do 
radionucleotide imaging to find out my ocardial inflammation early. 
Electromyography (EMG) was done to all the 50 cases in our study. 
EMG is a sensit ive indicator of muscle involvement even though muscle 
enzymes, biopsy were normal. In our study around 78% showed myopathic 
pattern compared to western study of 80%. 
We did muscle biopsy in 92% of patients in our study. Only 39% 
showed inflammatory changes consistent with inflammatory myositis. It may 
be due to patchy inflammation of muscle in Inflammatory Myosit is. 
In our study inflammatory markers like CRP, ESR are elevated in 
around 62% and 60% respectively. 
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CONCLUSION 
In out study, inflammatory myositis is more common in females than in 
males.  
In our study, myosit is is more common in overlap syndromes compared 
to Idiopathic Inflammatory Myosit is.  
In our study, among the overlap syndromes SLE with myositis overlap 
is more common. 
In our study, ILD was seen in 50% of the adult patients with NSIP 
being the most common. 
In our study, a symptomatic ECG abnormalities was common (48%). 
In our study, 58% of the patients showed inflammatory cells in the 
BAL study, out of which 52% of the patient had ILD changes by HRCT Lung 
In patients with myosit is, routine use of HRCT Lung and ECG 
evaluation is more useful.  
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A STUDY ON CARDIOPULMONARY 
MANIFESTATIONS IN INFLAMMATORY MYOSITIS 
 
Name :    Age:  Sex:  Occupation: 
Address: 
DOE:    RCC No.: 
Complaints: 
H/o.Present Illness 
 
H/o.Past Illness 
 
Personal History 
 
Treatment History 
 
Family History 
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General Examination 
Height:   Weight:   BMI: 
Pallor:   Icterus:   Lymphadenopathy: 
Pedal Edema:  Clubbing:   Skin: 
Nails:       Hair: 
 
Vital Signs 
PR:    BP:    RR:  Temp: 
Cardiovascular System: 
Respiratory System: 
Abdomen: 
Central Nervous System: 
 
Musculocellular System: 
   
 82 
INVESTIGATION 
Haemogram 
Hb:    TC:    DC: 
PLT:    RBC:    ESR: 
Immunological 
ANA: ELISA/Hep-2 IIF  ENA Profile:   CRP: 
RF: 
Bio-Chemistry 
Sugar:    Urea:    Creatinine: 
Bilirubin:   SGOT:   SGPT: 
ALP:    Total Protein:  Albumin: 
TGL:    Cholesterol:   CPK: 
LDH: 
Radiography 
1. Chest X-Rays:    2. HRCT Lung   
3. Echo Cardiogram     
Other investigations 
ECG:      PFT: 
Bronchoalveolar Lavage   Muscle Biopsy 
EMG Studies 
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 85 
 
Hb 
(gm/dl)
TC 
(Cells/cu
mm)
DC (P/ 
L/ E)
ESR 
(mm/hr)
Platelet 
(Cells/ 
Cumm)
Anti-
SM 
Ab
Anti- 
SM/U1 
RNP 
Ab
Anti- 
ro 
Ab
Anti-la 
Ab
Anti- 
SCL70
Anti 
Jo1 
Ab
OT PT Sr.Br CPK
1 Vijaya 44/F 55039 8 Dermatomyositis with ILD 8.2 9300 52/42/6 130 1.3 + - - - - - - - 286 196 0.6 25/0.8 28
2 Girija 19/F 54361 6 MCTD with ILD with PHT 9.4 9800 70/29/1 30 1.2 + - - + + - - - 35 46 0.9 30./1 60
3 Amutha 30/F 50604 18 Systemic Sclerosis/ ILD/ Myositis overlap 10.6 7800 64/32/4 30 1.8 + - - - - - - - 27 33 0.9 30/1. 953
4 Shoba 27/F 54266 18 MCTD with myositis overlap 10.3 7600 62/34/5 20 1.68 + - - + - - - - 119 200 1 28/1.2 992
5 Premila 48/F 47660 60 SLE with myositis overlap 10.8 8010 59/32/3 16 1.64 + - - - - - - - 168 122 0.7 24/.9 90
6 Usha 27/F 53366 8 SLE with myositis overlap 7.6 3400 67/29/4 100 1.4 + - - - - - - - 182 130 0.9 20/.9 200
7 Ilayanathi 16/F 53238 24 SLE with myositis overlap 11 7600 50/35/3 48 1.9 + Homogenous - - - - - - 23 21 1 20/.9 43
8 Noor Ayisha 13/F 53793 1 1/2 Polymyositis 10.4 7200 67/29/4 5 1.8 - - - - - - - - 18 20 1 36/.8 484
9 Nazeema 22/F 53795 2 Dermatomyositis  10 920 80/18/2 40 1.72 - - - - - - - - 33 18 0.8 17/.6 2635
10 Sahayaraj 28/M 53656 8 Dermatomyositis  11.8 6000 60/38/2 65 1.7 + - - - - - - - 54 76 0.6 15/1.1 950
11 Pitchayammal 48/F 53638 2 Dermatomyositis  9.8 6200 60/32/8 75 1.6 + - - - - - - - 156 256 1 30/1.0 200
12 Malliga 44/F 52945 3 Systemic Sclerosis Myositis Overlap 9.8 7500 57/35/8 50 1.7 + - - - - - + - 130 83 0.5 24/.5 80
13 Sasikala 35/F 54226 3 Dermatomyositis ILD 11 8300 56/42/2 86 2.15 + Homogenous - - - - - - 118 27 0.8 18/1.0 65
14 Leena 13/F 53766 3 SLE with myositis overlap 6.4 10600 68/28/4 160 1.54 + - ND ND ND ND ND ND 17 21 0.3 21/.9 932
15 Engamma 24/F 53796 3 SLE with myositis overlap 9.5 8400 60/38/2 25 1.5 + - - - - - - - 26 30 1 29/.9 110
16 Kaleema 54/F 52365 2 Dermatomyositis 10 10500 63/32/5 25 1.8 + - - - - - - - 124 30 1 25/.8 85
17 Maharani 23/F 53884 6 SLE with myositis overlap 10.2 8300 65/31/4 103 1.8 + - - - - - - - 114 60 0.6 29/.8 114
18 Kumar 33/M 52282 3 Polymyositis 13.4 8700 63/34/3 14 2.7 - - - - - - - - 161 191 0.5 28/.5 130
19 Nazeema Banu 24/F 54232 6 SLE with myositis overlap 9.8 7500 66/30/4 110 2.5 + - - - - - - - 72 26 0.7 27/1.0 48
20 Nalini 39/F 53524 12 SLE with myositis overlap 9 5200 63/33/4 100 1.76 + - - - - - - - 231 74 0.9 30/.7 278
21 Anandan 36/M 53450 30 Dermatomyositis with ILD 13.6 8000 54/42/4 110 1.4 + Speckled - - - - - - 25 15 0.8 26/.8 315
22 Vanitha 37/F 53404 12 MCTD Myositis Overlap 10.4 8200 63/32/5 30 2.6 + Speckled - + - - - - 24 19 1 24/.6 300
23 Selvi 17/F 53358 48 JDM/SLE overlap 9.6 7200 66/30/4 130 2.4 + Speckled - - - - - - 198 38 0.9 22/.8 300
24 Shoba Rani 20/F 53368 3 SLE with myositis overlap 9.8 7800 63/34/3 100 1.7 + Homogenous - - - - - - 88 20 0.9 20/.9 40
25 Sujatha 40/F 53168 7 year SLE with myositis overlap 10.4 6200 65/31/4 30 1.8 + Speckled - - - - - - 13 30 0.7 30/.9 300
26 Bhavani 9/F 55066 9 JDM 10.4 6500 79/18/3 26 1.5 + Speckled - - - - - - 91 51 0.5 25/.6 776
27 Guru Moorthy 39/M 53181 18 Dermatomyositis with ILD 13 7200 67/33/6 32 2.7 + Speckled - - - - - - 38 30 0.9 30/1.1 130
28 Pratap 60/M 522121 12 Dermatomyositis with ILD 9 6500 65/30/2 50 1.2 + Speckled - - - - - + 110 100 0.5 22/0.7 750
Duration of Illness (months) Diagnosis
Complete Blood Count
ANA/ ELISAS. No Name Age/ Sex RCC No ANA by HEP2
ENA Profile
RFT  Urea/Cr(mg/dl)
LFT Mus
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
Hb 
(gm/dl)
TC 
(Cells/cu
mm)
DC (P/ 
L/ E)
ESR 
(mm/hr)
Platelet 
(Cells/ 
Cumm)
Anti-
SM 
Ab
Anti- 
SM/U1 
RNP 
Ab
Anti- 
ro 
Ab
Anti-la 
Ab
Anti- 
SCL70
Anti 
Jo1 
Ab
OT PT Sr.Br CPKDuration of Illness (months) Diagnosis
Complete Blood Count
ANA/ ELISAS. No Name Age/ Sex RCC No ANA by HEP2
ENA Profile
RFT  Urea/Cr(mg/dl)
LFT Mus
29 Gandhimathi 32/F 53109 10 SLE with myositis overlap 8.7 5900 81/18/1 40 1.06 + Homogenous - - - - - - 77 72 0.5 25/.6 70
30 Sugamathi 27/F 53088 6 MCTD Myositis Overlap 10.2 6100 57/42/1 110 2.6 + Speckled + + - - - - 245 873 0.8 26/.8 220
31 Thara Bhai 63/F 42392 10 years Polymyositis 9.6 9200 63/33/4 80 2.66 - - - - - - - - 22 41 0.8 30/.1.1 402
32 Annakkodi 13/F 53054 6 years JDM 11.9 6700 66/30/4 75 1.6 - - - - - - - - 16 16 0.6 20/.9 60
33 Rekha 24/F 53077 3 SLE with myositis overlap 5.3 7100 51/45/4 70 2.39 + Homogenous - - - - - - 61 148 0.5 25/.8 350
34 Sundari 42/F 53003 18 SLE with myositis overlap 8 8200 54/41/5 46 2.01 + Homogenous - - - - - - 124 90 1.1 30/1.2 550
35 Nadhiya 23/F 53396 5 years SLE with myositis overlap with ILD 9.2 7300 66/30/4 96 2.01 + Homogenous - - - - - - 23 44 0.9 30/.7 30
36 Murugan 8/MCH 53528 2 JDM 10.6 7800 62/33/5 34 1.85 - Speckled - - - - - - 82 293 0.8 25/.5 2192
37 Lakshmi 50/F 53604 9 SLE with Myositis Overlap 8.9 5300 56/34/7 50 1.7 - RIM - - - - - - 99 88 0.9 30/.8 300
38 Thilagavathy 40/F 53932 5 Years Systemic Scelerosis with myositis overlap with ILD 9 7700 50/35/5 72 1.79 - Speckled - + - - - - 60 25 0.8 32/1 30
39 Stella Rani 50/F 52966 6 Dermatomyositis with ILD 9.4 7800 60/35/5 20 1.78 + Homogenous - - - - - - 316 106 0.6 36/.9 750
40 Raja 39/M 54944 3 SLE myositis overlap 10.8 8500 68/30/2 15 1.54 + Homogenous - - - - - - 159 74 0.5 15/.7 1536
41 Poulia 40/F 51248 7 Systemic Sclerosis myositis Overlap with ILD 10.4 7600 67/29/4 17 1.7 + Speckled + - - - - - 123 144 0.9 26/.8 2117
42 Padma 22/F 51214 2 years SLE myositis overlap 10.6 6200 60/30/6 15 1.7 + RIM - - - - - - 220 90 0.3 20/1.0 15
43 Sekar 45/M 53781 6 Polymyositis 9 5500 60/36/2 35 1.5 + Speckled - - - - - - 140 110 0.6 30/1.0 750
44 Sathya 13/MCH 53784 3 years JDM 11 7500 52/30/3 40 1.7 + Speckled - - - - - - 110 78 0.8 20/1.1 950
45 Kalaimani 33/F 54937 2 years Systemic Sclerosis with Myositis Overlap with ILD 9.5 6700 56/42/2 106 1.49 + Speckled - - - - + - 109 15 0.6 20/.9 318
46 Govindammal 32/F 53975 8 Dermatomyositis with ILD 12 9000 45/30/6 60 2.2 + - - - - - - + 140 130 0.5 26/1.0 770
47 Periyasamy 65/M 53280 5 Dermatomyositis 8 11000 70/28/2 70 1.2 + - - - - - - - 116 178 0.9 34/1.2 900
48 Chandran 7/MCH 53270 1 year JDM 9 7200 56/34/1 30 1.3 + Speckled - - - - - - 100 92 0.2 20/1.0 750
49 Rama Lakshmi 30/F 53672 3 SLE myositis overlap 9 5000 72/28/1 25 68000 + RIM - - - - - - 112 120 0.8 25/.9 130
50 Loganayagi 72/F 56524 3 SLE myositis overlap 6.8 4100 85/10/5 42 2.36 + Speckled - - - - - - 56 54 0.7 18./.8 550
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
LDH
499
150
450
2125
475
350
623
112
3814
574
156
2105
1058
650
1189
1885
950
1684
779
541
705
344
664
1052
787
1738
110
110
scle 
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
LDH
scle 
566
1691
230
278
2016
900
463
631
655
56
2461
90
750
850
1100
730
131
1102
950
1300
950
850
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
Inflammatory Cells 
(Lymphocyts, 
Neuprothils)
AFB Gram Stain Culture
N Lower Zone, Ground glass opacity present + - - - NSTW Mild AR + Myopathic Pattern + Perifascicular atrophy perivascular inflammatory infiltrates + >6 RP N
N Bilateral ground glass opacity with bronchiectatic changes + + - - -
P Pulmunale 
+ RA, RV Dilated N N N RP N
N Bilateral lower zone opacity + + - - - N N N N >6 RP N
N N - - - - NSTW N Myopathic Pattern + N N Poor Flow N
N N + - - - NSTW N Myopathic Pattern + N N N N
N N - - - - NSTW N Myopathic Pattern + N N N Alb 1+, 1-2 Deposits
N N ND ND ND ND
Juvenile 
Twave 
inverstion 
N Myopathic Pattern + ND >6 ND N
N N ND ND ND ND N N Myopathic Pattern + N >6 ND N
N N - - - - N - Myopathic Pattern + Muscle Degeneration +/ regeneration/ perivascular inflammatory infiltrates + >6 N N
N Sub pleural down class opacity noted in the Lt lower lobe posterolateral segment Inflammatory cells + - - - N - Myopathic Pattern + N >6 RP N
N N + - - - N N Myopathic Pattern + Focal perifascicular atrophy and lymphocytic infiltration + >6 N N
N N - - - -
Non specific 
ST/T wave 
changes +
N Myopathic Pattern + N >6 Poor Flow N
N Ground glass opacity in both postero basal segment + + - - - N N N Mild atrophy minimal inflammatory cells present >6 RP+OP N
N ND ND ND ND ND N N N N N ND N
N Rt pleural effusion Lt upper low ? Consolidation Lymphocytosis + - - - N Moderate MR present Myopathic Pattern + Inflammatory infiltrates + N RP+OP N
N N + ND ND ND N N N N >6 N N
Cardiomegaly + N - - - - Low Voltage Cxs
Mild PE + Global 
hypokinesia +, EF34% N N N N N
Lowerzone 
opacity + N - - - - NSTW N N N N N N
Bilateral pleural 
effusion + Bilateral pleural effusion + - - - - NSTW N Myopathic Pattern + N >6 RP
10-15 
Puscells
N N - - - - N TR Mild Myopathic Pattern + N >6 N Alb 1+, 1-2 Deposits
N Lt Lower lobe ground glass opacity with bronchectatic changes + + - - - N N Myopathic Pattern +
Myophagocytosis perifascicular, interstitial inflammation +, 
Regenerating fibers + >6 RP+OP N
Bilateral upper 
zone haziness +
Bilateral apical fibrosis, ground glass opacity 
in basal segment both lower lobes with 
bornchectatic changes
+ - - - N N Myopathic Pattern + Inflammatory cells +, regenerating muscle fibers seen, EMG myopathic pattern >6 RP N
N Reticulo nodular pattern in Rt lower lobe basal segment ND ND ND ND N N Myopathic Pattern +
Inflammatory cells with perifascicular atrophy, perivascular 
infiltration + N RP N
Cardiomegaly + N - - - - N MR Mild Myopathic Pattern + ND >6 N Alb 2+
N N N N N N N N N N >6 N Alb 2+
N ND ND ND ND ND N N Myopathic Pattern + ND >6 ND N
N Bilateral honey combing Inflammatory Cells Present - - - N N N N >6 N N
N Bilateral lower zone opacity + Inflammatory Cells Present - - - N N Myopathic Pattern +
Inflammatory cells with perifascicular atrophy, perivascular 
infiltration + >6 N N
CXR EMG Muslce BiopsyHRCT Lung ECG ECHO
BAL
CRP 
(Normal 
<6mg/l)
PFT Urine Routine
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
Inflammatory Cells 
(Lymphocyts, 
Neuprothils)
AFB Gram Stain CultureCXR EMG Muslce BiopsyHRCT Lung ECG ECHO
BAL
CRP 
(Normal 
<6mg/l)
PFT Urine Routine
N N N - - - N N Myopathic Pattern + ND N N N
Bilateral 
increased BVM + Lt lung ground glass opacity + Present - - - N N Myopathic Pattern + Inflammatory cells present diffuse N Poor Flow N
Increased BVM Bilateral reticulo nodular pattern + Present - - - N Mild MR TR Myopathic Pattern + Inflammatory cell, Muscle atrophy + >6 RP Alb 2+
N ND ND ND ND ND N N Myopathic Pattern + Inflammatory cells +, with perifascicular atophy, perivascular infiltration + >6 N N
N
Lt. upper lobe modular opacity +, ground 
glass opacity + on Rt side, Thickened 
septum +
Present - - - N Mild PE +  Myopathic Pattern + N N RP N
CT ratio >0.5 N N - - - N Mild PE +, Mild MR +
Myopathic Pattern +, 
No spontaneous 
activity
N N N N
Bilateral mid 
zone infiltrates +
Honey combing in basal segmeng of Both 
lower lobes, reticular opacity in Rt upper lobe Present - - - N
Main pulomary artery 
dilated, Atrial septal 
aneurysm with intact IAS
Myopathic Pattern + Inflammatory cells + >6 RP N
N ND ND - - - N N Myopathic Pattern + Myophagocytosis perifascicular, interstitial inflammation +, Regenerating fibers + >6 ND N
N N ND - - - N N Myopathic Pattern + Inflammatory cells + N RP Alb 2+
CT ratio >0.5 Bilateral honey combing + Present - - - NSTW N N N >6 RP N
CT ratio >0.5 Lt lower zone ground glass opacity +, Rt. Lung fibrotic strongs + Present - - - NSTW N Myopathic Pattern + Perifascicular atrophy perivascular inflammatory infiltrates + >6 RP N
N N N - - - NSTW N Myopathic Pattern + N Neg N N
N Bilateral sub pleural opacity +, Suggestive of early ILD Present - - - NSTW N Myopathic Pattern + N >6 N N
N N - - - - NSTW N Myopathic Pattern + N Neg N N
N N N - - - NSTW N Myopathic Pattern + N >6 N N
N ND ND ND ND ND NSTW N Myopathic Pattern + N >6 ND N
N Bilateral ground glass opacity noted in the medial segment Rt. Middle lobe Present - - - N N Myopathic Pattern + N >6 RP N
N Bilateral lower zone opacity + Present - - - N N Myopathic Pattern + Inflammatory cells +, perifascicular region, Muscle fibres, regeneration, degeneration +, perifascicular atrophy + >6 RP N
N N N - - - LVH + LVH Myopathic Pattern + N >6 RP N
N ND ND ND ND ND N N Myopathic Pattern + N >6 ND N
N Effusion Rt side fibrosis of 6th basal segment Rt lower lobe Present - - - N N Myopathic Pattern + N Neg Poor Flow Alb 3+ Dep+
N
Rt. Lower lobe postero basal segment 
nodular opacity +, suggestive of intrestitial 
pneumonitis
Present - - - N N N N >6 N Alb 2+ Dep+
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
--
+
-
-
+
-
-
+
-
+
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
+
+
RF
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
RF
-
+
-
-
-
-
-
-
-
-
-
-
+
-
-
-
+
-
-
-
-
-
(+)- Positive
(RSTV) Non spectific T Wave Abnormalities
(-) Negative
(CXZ) Complexes
(ND) Not Done
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ABSTRACT 
BACK GROUND: 
Inflammatory Myopathies are a group of auto immune hetrogenous 
muscle disorders with prominent system involvement. The Cardio pulmonary 
complication of inflammatory myopathies usually results in increased 
morbidity and mortality. 
AIM  
To find out the various cardio pulmonary manifestation in 
inflammatory myosit is 
MATERIALS AND METHODS 
 The cross sectional study was conducted from February 2011 to 
January 2012 in the Department of Rheumatology, Madras Medical College, 
Chennai-3. 50 Patients fulfilled inclusion criteria, Bohan & Peter criteria for 
idiopathic inflammatory myosit is and myositis overlap syndromes. All the 
Patients are subjected to clinical examination, CBC, RFT, LFT, CRP, RF, 
Muscle enzymes (CPK, LDH, SGOT, SGPT) ECG, ECHO, PFT, HRCT Lung, 
CXR, Broncho Alveolar Lavage (BAL), auto antibody profile (ANA, ENA 
Profile), muscle biopsy, ultra sound abdomen and EMG studies.  
RESULTS: 
In our study 68% were Female, 16% were Male, 10% were Female 
children and 6% were Male children. Mean age for females (33.9 years), 
males (43.12 years), Male children (9.3 years), Female children (15.6 years). 
The prevalence of overlap myositis 60%, SLE myosit is overlap 65%, ANA 
 
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positivity 83%, ANA speckled 55%, muscle enzymes elevated 67% , HRCT 
Lung 50% showed ILD, PFT abnormal in 54.5%, BAL 57.5% abnormal, 
nonspecific ST T-wave changes 44%, EMG 78% myopathic pattern, CRP 
(62%) and ESR (60%) elevated.  
CONCLUSION: 
Inflammatory myositis is more common in females, myositis is more 
common in overlap syndromes, ILD was seen in 50% of the adult patients, a 
symptomatic ECG abnormalities was common. BAL Showed inflammatory 
cells in 57.5% .  
KEY WORDS:  
Inflammatory myositis, Overlap syndromes, SLE, ILD,  
